|
Circulating Tumor DNA for Minimal Residual Disease in Colon Cancer: Ready for Prime
Time?
Apr 16, 2026 Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) Apr 16, 2026 What Money Cannot Buy: Addressing the Socioeconomic Status Ceiling Effect for Black Patients Across Cancer Types Apr 16, 2026 Diminishing Returns Among Black Patients With Cancer: The Intersection of Race and Neighborhood Socioeconomic Status Apr 16, 2026 Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation? Apr 16, 2026 Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603 Apr 16, 2026 Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) Apr 16, 2026 Circulating Tumor DNA for Minimal Residual Disease in Colon Cancer: Ready for Prime Time? Apr 16, 2026 Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial Apr 16, 2026 Diminishing Returns Among Black Patients With Cancer: The Intersection of Race and Neighborhood Socioeconomic Status Apr 16, 2026 What Money Cannot Buy: Addressing the Socioeconomic Status Ceiling Effect for Black Patients Across Cancer Types Apr 16, 2026 Body Size and Bladder Cancer Risk: A Pooled Analysis of Prospective Studies From the National Cancer Institute Cohort Consortium Apr 16, 2026 Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival Apr 16, 2026 Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 Reply to: Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 Reply to: Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 |
Causal machine learning–guided personalized immunochemotherapy strategies in intrahepatic cholangiocarcinoma (CMICC). Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 1-1, July 2026. <br/> 2026-07-01T07:00:00Z Transformer-based multi-omics synthesis for early risk stratification and preventive surveillance in liver oncology. Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 10-10, July 2026. <br/> 2026-07-01T07:00:00Z Liposomal irinotecan (HR070803) plus fluorouracil and bevacizumab as second-line treatment in advanced colorectal cancer: Cohort A results from a phase 2 trial. Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 100-100, July 2026. <br/> 2026-07-01T07:00:00Z 68Ga-NODAGA-SNA009: A first-in-class single-domain antibody probe for rapid PET imaging of GPA33 in colorectal cancer. Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 101-101, July 2026. <br/> 2026-07-01T07:00:00Z Addressing radiologist inter-reader variability in gastric cancer T staging: A prospective study using the dual-module AI model, TRACE. Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 102-102, July 2026. <br/> 2026-07-01T07:00:00Z Circulating tumor suppressor microRNAs as minimally invasive biomarkers for early detection of colorectal cancer. Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 103-103, July 2026. <br/> 2026-07-01T07:00:00Z Endoscopic submucosal dissection for early gastrointestinal neoplasms: A prospective study of 50 cases in 45 patients in Vietnam. Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 104-104, July 2026. <br/> 2026-07-01T07:00:00Z RelB/ILF2–GM-CSF loop to sustain MDSC-mediated prostate cancer immunosuppression. Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 105-105, July 2026. <br/> 2026-07-01T07:00:00Z Neoadjuvant anti-PD-1 monotherapy in MSI-H locally advanced gastric cancer: 3-Year survival without surgery. Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 106-106, July 2026. <br/> 2026-07-01T07:00:00Z Adebrelimab plus interventional and targeted therapy for unresectable hepatocellular carcinoma: A single-arm, real-world study. Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 107-107, July 2026. <br/> 2026-07-01T07:00:00Z Hepatic arterial infusion chemotherapy plus immune checkpoint inhibitors and lenvatinib for locally advanced biliary tract cancer: A single-arm, exploratory study. Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 108-108, July 2026. <br/> 2026-07-01T07:00:00Z Pathological complete response after neoadjuvant chemoimmunotherapy with toripalimab or camrelizumab in esophageal squamous cell carcinoma: A systematic review and meta-analysis. Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 109-109, July 2026. <br/> 2026-07-01T07:00:00Z An integrative multi-omics machine learning framework for precision metastasis prediction and clinical staging in non-small cell lung cancer. Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 11-11, July 2026. <br/> 2026-07-01T07:00:00Z Neoadjuvant chemotherapy plus serplulimab and immuno-response molecular subtype for pMMR locally advanced rectal cancer (FIRM). Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 110-110, July 2026. <br/> 2026-07-01T07:00:00Z A GAN-based multimodal framework for preoperative response prediction in HER2-negative locally advanced gastric cancer treated with neoadjuvant chemoimmunotherapy. Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 111-111, July 2026. <br/> 2026-07-01T07:00:00Z Nodal status–guided postoperative radiotherapy after neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter cohort study. Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 112-112, July 2026. <br/> 2026-07-01T07:00:00Z |
For Those Left Behind
An ICU physician believed letting her father die at home meant comfort, dignity, control, family close by, and the quiet reassurance of hospice. But she didn’t realize what it would require of her family. 2026-07-04
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma In patients with resected clear-cell renal-cell carcinoma, pembrolizumab plus belzutifan led to higher disease-free survival than pembrolizumab alone but an increased risk of grade 3 or higher adverse events. 2026-07-02
The Invisible Load of Cognitive Symptoms Patients with shrinking cognitive bandwidth may feel their disability keenly in daily life, even if they can pass a controlled test of cognitive capacity. How should clinicians approach and care for them? 2026-07-02
Hospital Policy of Tranexamic Acid to Reduce Transfusion in Major Noncardiac Surgery In a cluster-randomized trial involving patients having major noncardiac surgery, tranexamic acid reduced the need for red-cell transfusion during hospitalization and was noninferior to placebo for venous thromboembolism within 90 days. 2026-06-25
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas Among 38 patients who received CAR T-cell therapy for refractory or relapsed B-cell lymphomas, lymphoma-free survival at 10 years was 32% for large B-cell lymphomas and 47% for follicular lymphoma. 2026-06-25
TRACTION for Greater Surgical Use of Tranexamic Acid Every year, many millions of surgical patients worldwide are unnecessarily exposed to a higher-than-necessary risk of blood transfusion because they do not receive a single dose of tranexamic acid just before the surgery. This failing is due not to a lack of high-quality scientific evidence on the overall safety, efficacy,... 2026-06-25
When Health Costs No Longer Count — Air Pollution and EPA Rulemaking The EPA has decided to stop considering the monetary value of public health benefits in federal rulemaking related to air pollution. This decision could have profound health consequences. 2026-06-25
Response to Crizotinib in Infantile Fibrosarcoma with TFG::MET Gene Fusion A rapid response to crizotinib after failure of chemotherapy in a patient with infantile fibrosarcoma with a TFG::MET fusion underscores the value of molecular profiling in atypical disease. This approach could enable limb sparing. 2026-06-25
Prehospital Whole Blood in Traumatic Hemorrhage — A Randomized Controlled Trial Among patients with traumatic hemorrhage, prehospital whole-blood transfusion was not superior to standard transfusion with red-cell and plasma components in reducing the risk of death or massive transfusion. 2026-06-18
Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial Among patients with moderate or severe PTS, the addition of endovascular therapy to standard care resulted in less severe PTS and better quality of life at 6 months than standard care alone but with a higher risk of bleeding. 2026-06-18
Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage Among patients with traumatic hemorrhage, prehospital transfusion of whole blood did not result in lower 30-day mortality than transfusion of plasma or red cells. Outcomes did not differ according to the storage age of blood. 2026-06-18
Management of Differentiated Thyroid Cancer This review of the evolving management of differentiated thyroid cancer highlights overdiagnosis of low-risk disease, dynamic risk stratification, active surveillance or ablation, targeted therapies, and active patient involvement. 2026-06-18
Case 17-2026: A 74-Year-Old Man with Pancytopenia A 74-year-old man with a recent orthotopic heart transplantation was admitted to the hospital because of persistent pancytopenia that resulted in serial transfusions of packed red cells. A diagnosis was made. 2026-06-18
Stenting for Post-Thrombotic Syndrome — A Step Forward Post-thrombotic syndrome is the most common chronic complication of deep-vein thrombosis (DVT), affecting 20 to 50% of patients with DVT and causing debilitating symptoms involving the limbs — including pain, swelling, skin changes, and venous ulcers — that substantially reduce quality of life and impose considerable socioeconomic burden.1 ... 2026-06-18
Prehospital Whole Blood for Traumatic Hemorrhage — Consistent Evidence from Two Randomized Trials Hemorrhagic shock remains the leading cause of preventable death after injury.1 Over the past two decades, early administration of blood products has transformed care for patients with bleeding. The Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial2 established that among patients with severe trauma and... 2026-06-18
Stemness as the Engine of Checkpoint Durability The clinical benefits of checkpoint inhibitors in the treatment of cancer often wane. A preclinical study points to a potential strategy for a more durable effect. 2026-06-18
Immunosuppression-Associated Peripheral T-Cell Lymphoma A 66-year-old man with a history of Crohn’s disease treated with long-term adalimumab presented with fever and swelling of both knees. Analysis of a biopsy sample of the left knee synovium showed an atypical T-cell infiltrate. 2026-06-18
Intravenous Artesunate in Artemisinin-Resistant Severe Malaria in Uganda In an African study of severe malaria in children with partially artemisinin-resistant parasites with PfK13 mutations, artesunate did not lead to worse outcomes, which suggests that parenteral artesunate may still be used. 2026-06-18
Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema In a phase 3, randomized trial of lonvo-z, an in vivo gene editing therapy, patients with hereditary angioedema who received the drug had a significantly lower attack rate than those who received placebo. 2026-06-13
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma Talquetamab–daratumumab, with or without pomalidomide, led to longer progression-free survival than daratumumab-based standard care in relapsed or refractory myeloma. More than 75% of patients had grade 3 or higher adverse events. 2026-06-13
|
|
|
| |||
|
[Editorial] Historic moments
Attending large scientific conferences can be an endurance test. The sunrise sessions, the multiple parallel tracks, the thousands of steps walking back-and-forth from one end of a convention centre to the other, and the evening receptions, all combined with meetings with colleagues, old and new. But occasionally, it becomes apparent that the conference in question is different, that something historic has happened. This year's American Society of Clinical Oncology (ASCO) annual meeting was one such occasion, evoking memories of other examples such as ASCO 2010 and the 2025 San Antonio Breast Cancer Symposium (SABCS). Wed, 01 Jul 2026 00:00:00 -0700
[Comment] SUBITO: validating biology, not intensity The SUBITO trial, presented by Rianne L Seefat and colleagues in The Lancet Oncology,1 revisits the long-standing debate surrounding high-dose chemotherapy with autologous stem-cell rescue in patients with high-risk early breast cancer, exploring its potential role in the modern era of therapies targeted to homologous recombination-deficient (HRD) tumours. Wed, 01 Jul 2026 00:00:00 -0700
[Comment] Customised radiation after neoadjuvant chemotherapy in breast cancer Although oestrogen receptor, progesterone receptor, and HER2 receptor expression status help to tailor neoadjuvant systemic therapy regimens in patients with breast cancer, the response to treatment is arguably more prognostic than is receptor status itself. The amount of residual disease following neoadjuvant therapy, as calculated by the residual cancer burden index, correlates with disease recurrence independent of stage or receptor status.1 In patients with high risk of recurrence based on substantial residual disease, trials such as KATHERINE and CREATE-X provide data to support escalation of adjuvant systemic therapy, providing truly personalised medicine for patients with breast cancer. Wed, 01 Jul 2026 00:00:00 -0700
[Comment] Preliminary results from PRIMARY2: bringing colour to a grey arena A non-invasive diagnostic test that enables us to safely avoid an invasive test is valuable. Historically, an elevated prostate-specific antigen (PSA) was the primary driver for a prostate biopsy. This approach was refined as a result of multiple large trials demonstrating the benefit of an MRI-based triage system, with MRI generally increasing the detection of clinically significant prostate cancer while reducing prostate biopsies.1 Wed, 10 Jun 2026 22:30:01 +0000
[Comment] Radiotherapy dose escalation in glioblastoma: the thin ice of of historical controls In The Lancet Oncology, Frank A Giordano and colleagues report the outcome of the INTRAGO II trial, a randomised, phase 3 study investigating the benefit of radiotherapy dose intensification in 314 patients with glioblastoma. The authors must be congratulated for successfully completing a technically complex trial. The radiotherapy boost was given with an additional 30 Gy single dose of intraoperative radiation by use of low-energy x-rays emitting 50 kV photons to the resection cavity, in addition to standard-of-care chemoradiotherapy. Wed, 01 Jul 2026 00:00:00 -0700
[Comment] Artificial intelligence volumetry in mesothelioma: ready for deployment? Pleural mesothelioma is an uncommon, asbestos-associated cancer. Unlike most primary tumours, which grow spherically, mesothelioma conforms to the complex shape of the pleural cavity. As the disease progresses, multifocal tumour nodules coalesce and thicken to produce a crescent-shaped rind encasing the lung. Tumour foci might invade into adjacent structures, with limited between-plane resolution on routine imaging. This morphological complexity, combined with a typical pleural surface area of around 4000 cm2, makes radiological quantification extremely challenging. Wed, 17 Jun 2026 22:30:04 +0000
[Comment] Delivering transformational change for patients and the environment through England's National Cancer Plan The National Cancer Plan for England, published in February, 2026, sets out ambitious plans for the future of cancer care in England over the next 10 years.1 Overlooked in the plan, however, is the need to align these plans with the legal commitment of the National Health Service (NHS) to developing an environmentally sustainable health-care system, reducing health care-associated greenhouse gas emissions to net zero by 2045.2 Many policies set out in the plan could contribute to achieving this goal—realising co-benefits for health and environment—but the potential environmental impacts of some proposals need careful evaluation before and during implementation. Wed, 01 Jul 2026 00:00:00 -0700
[Correspondence] The intermediate-risk gap in AI-based breast cancer stratification Gil Shamai and colleagues1 have produced the most methodologically rigorous computational pathology model to date for recurrence-score estimation in hormone receptor-positive, HER2 (also known as ERBB2)-negative early breast cancer. Leveraging TAILORx randomised treatment assignments to show differential chemotherapy benefit by menopausal status—a distinction no previous computational pathology study has achieved—the model raises the bar for the field. The minimal calibration approach, requiring only 100 slides and no local genomic labels, addresses barriers to deployment in resource-limited settings. Wed, 01 Jul 2026 00:00:00 -0700
[Correspondence] The intermediate-risk gap in AI-based breast cancer stratification – Authors' reply We thank Koinis and colleagues for raising a concern worth clarifying, as other readers might share it. They describe the intermediate-risk population as the group in which stratification is most needed, and argue that our model adds little value there. This conflates two distinct concepts: intermediate clinical or genomic risk and intermediate artificial intelligence (AI) risk. Our AI model is, itself, a stratification tool that resolves subpopulations within the conventionally uncertain clinical and genomic groups, precisely where it is most needed. Wed, 01 Jul 2026 00:00:00 -0700
[Correspondence] Terbium-161 might be superior to lutetium-177 for oligometastases Bastiaan M Privé and colleagues reported on the phase 2 trial BULLSEYE, which investigated prostate-specific membrane antigen (PSMA) radioligand therapy with [177Lu]Lu-prostate-specific membrane antigen-617 ([177Lu]Lu-PSMA-617) in patients with PSMA-expressing oligometastatic (≤5 metastases) hormone-sensitive prostate cancer (HSPC), in a setting of biochemically recurrent prostate cancer with a fast prostate-specific antigen (PSA) doubling time of less than 6 months.1 Patients were randomly assigned to 177Lu-PSMA-617 every 6 weeks for up to four cycles or to deferred androgen deprivation therapy (ADT) with active monitoring. Wed, 01 Jul 2026 00:00:00 -0700
[Correspondence] Terbium-161 might be superior to lutetium-177 for oligometastases – Authors' reply We thank Elif Hindié and colleagues for their thoughtful comments on our recent Article.1 Interest in higher linear energy transfer (LET) radiopharmaceuticals, such as terbium-161 (161Tb), has recently increased.2 161Tb resembles lutetium-177 (177Lu) in its decay but additionally emits low-energy conversion electrons and Auger electrons with high LET. These electrons could induce greater genotoxicity at the cellular level,3 raising the hypothesis that micrometastases could be more effectively treated, similar to proposed advantages of alpha-emitters. Wed, 01 Jul 2026 00:00:00 -0700
[Correspondence] Chemotherapy ports and the overlooked infrastructure of cancer care We write as clinicians and cancer survivors who underwent prolonged chemotherapy for oesophageal cancer. Our experiences highlight how access to implantable venous access devices (chemotherapy ports) can shape treatment quality, adherence, and dignity. Although standard in high-income settings, these devices remain unavailable or unaffordable in low-income and middle-income countries (LMICs), revealing an overlooked inequity in cancer care infrastructure. Wed, 01 Jul 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2025; 26: e369–80 Al-Thani MBH, Subramanian M, Halabi N, et al. Qatar national cancer care and research: pioneering strategies for global health excellence. Lancet Oncol 2025; 26: e369–80—In this Series paper, the labels for figure 2A have been corrected so that Qatar is the red line and the USA is the blue line. These corrections have been made to the online version as of June 29, 2026. Wed, 01 Jul 2026 00:00:00 -0700
[News] PMI faces questions over cigarette marketing and smoke-free commitments Over the past 10 years, Philip Morris International (PMI; headquartered at Stamford, CT, USA), a tobacco company, has repeatedly stated its intention to deliver a smoke-free future. According to the PMI website, it is “actively accelerating the decline of cigarette smoking beyond what traditional tobacco control measures can achieve alone.” Nonetheless, a new international advertising drive featuring PMI's flagship brand Marlboro has prompted critics to question the company's commitment to ending sales of combustible cigarettes. Fri, 29 May 2026 22:30:02 +0000
[News] Spain expands breast cancer screening programme The Public Health Commission in Spain has approved the expansion of the national breast cancer screening programme to include women aged 45–74 years. Fri, 29 May 2026 22:30:02 +0000
[News] Cancer screening expands as implementation gaps remain On May 26, 2026, the European Cancer Organisation published the European Cancer Screening Policy Index 2026; on May 27, 2026, the American Cancer Society updated its colorectal cancer screening guidance to include blood-based testing for some adults; and Indonesia added colorectal cancer screening to its National Free Health Checkup programme for people aged 45 years and older who are at high risk. These developments come as health systems are under pressure not only to detect cancer earlier, but to ensure that screening is organised, equitable, and followed by diagnosis and care. Thu, 04 Jun 2026 22:30:01 +0000
[News] 2026 ASCO Annual Meeting To a standing ovation in the Plenary Session, Brian Wolpin (Dana-Farber Cancer Institute, Boston, MA, USA) on behalf of an international team of researchers presented remarkable data from the RASolute 302 phase 3 trial, which showed a doubling of overall survival for patients with metastatic pancreatic adenocarcinoma. Pancreatic cancer is notoriously difficult to treat, but oncogenic RAS mutations are typically seen in more than 90% of cases, offering a unique opportunity for therapy. Daraxonrasib is a new oral, RAS(ON) multiselective, tri-complex inhibitor of mutant and wild type RAS. Thu, 04 Jun 2026 22:30:00 +0000
[News] French MPs vote for sharp cuts in cadmium content in fertilisers The French National Assembly, or the lower house of Parliament, has adopted a private member's bill on a first reading to scale down the amount of cancer-causing cadmium used in phosphate fertilisers in France, from 90 mg/kg to 20 mg/kg by 2030. Thu, 11 Jun 2026 22:30:01 +0000
[News] UK prostate cancer screening trial to include more Black men The UK Government has pledged £20 million to help improve prostate cancer research and treatment, including the expansion of a landmark screening trial to include all Black men who are eligible. Thu, 11 Jun 2026 22:30:01 +0000
[News] Almost a third of Americans set to live in jurisdictions allowing assisted dying Campaigners say the USA will reach a “monumental” juncture in September, 2026, when a total of 14 jurisdictions will legally allow medical aid in dying (MAID) after laws in the states of New York and Illinois come into force. Thu, 18 Jun 2026 22:30:02 +0000
[News] India's cancer drugs shortages mitigated through price increase The price of platinum-based cancer drugs in India has been raised in response to a nationwide shortage, following Government approval last week. Thu, 18 Jun 2026 22:30:02 +0000
[Perspectives] Should regional nodal irradiation be omitted in patients with node-positive breast cancer converting to node-negative after neoadjuvant chemotherapy? *Sachin R Jhawar, Jose G BazanDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43212, USA (SRJ); Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA (JGB) Wed, 01 Jul 2026 00:00:00 -0700
[Perspectives] OncoCorridor: connecting patients with cancer in conflict zones to treatment centres worldwide Over 2 billion people currently reside in conflict-affected areas. For millions of people affected by cancer in these areas, disruptions in health services lead to treatment delays or interruptions and, ultimately, amenable deaths. That people should endure both conflict and avoidable cancer death is a double injustice our professional oaths oblige us to confront. The OncoCorridor initiative, led by OncoDaily and the Institute of Cancer and Crisis, aims to reduce avoidable deaths from people diagnosed with cancer in conflict-affected regions by establishing a global network that connects them with treatment centres worldwide. Mon, 18 May 2026 13:00:01 +0000
[Articles] Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial Aumolertinib in combination with chemotherapy significantly improved progression-free survival. Although this regimen was associated with increased toxicity, the side-effects were managed with dose adjustment and supportive treatment aligned with clinical practice. Long-term follow-up is required to assess overall survival. The AENEAS2 study provides evidence to guide clinical practice regarding EGFR-TKIs and their combination use in treating patients with advanced EGFR-mutated NSCLC. Tue, 16 Jun 2026 09:52:47 +0000
[Articles] Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial These data demonstrate that targeting HRD yields promising outcomes in stage III, HER2-negative, HRD breast cancer and that intensified chemotherapy with autologous stem cell rescue does not provide any advantage over state-of-the-art chemotherapy plus olaparib. Wed, 01 Jul 2026 00:00:00 -0700
[Articles] Tailoring radiotherapy in cT1–2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry study Tailoring locoregional radiotherapy in cT1–2N1 breast cancer (with ≤3 nodes at imaging) to the nodal response after primary systemic therapy resulted in a low 10-year locoregional recurrence rate, with promising recurrence-free interval and overall survival. By (partially) omitting radiotherapy based on nodal response after primary systemic treatment, possible morbidity caused by the radiotherapy can be avoided, which could improve patients’ quality of life. Wed, 01 Jul 2026 00:00:00 -0700
[Articles] Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer Breast cancer mortality at 20 years was significantly lower in the IM-MS irradiation group, whereas non-breast cancer mortality was numerically higher in the IM-MS irradiation group after 15 years, resulting in no long-term benefit of IM-MS irradiation on overall survival. Our results emphasise the importance of very long-term follow-up and advanced irradiation techniques to reduce the dose to organs of interest. Wed, 01 Jul 2026 00:00:00 -0700
[Articles] SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial The ARTO trial showed significant benefit in overall survival with the addition of MDT to systemic therapy versus systemic therapy alone. Wed, 01 Jul 2026 00:00:00 -0700
[Articles] Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial [68Ga]Ga-PSMA-11 PET-CT could have the potential to improve the diagnostic pathway of patients with a high clinical risk but non-suspicious or equivocal prostate MRI. Further research, including health-economic analyses and validation with other PSMA radiopharmaceuticals, are needed to confirm the clinical implementation and generalisability of this approach. Wed, 10 Jun 2026 22:30:01 +0000
[Articles] Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial Perioperative systemic therapy cannot be recommended in all patients with resectable colorectal peritoneal-only metastases. Wed, 01 Jul 2026 00:00:00 -0700
[Articles] Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial Instant, spatially precise dose escalation with intraoperative radiotherapy added to standard of care did not improve outcomes, questioning the value of further local dose intensification in resectable glioblastoma. Wed, 01 Jul 2026 00:00:00 -0700
[Articles] Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study ARTIMES-based progression-free survival improves prognostic stratification and shows better trial-level surrogacy for overall survival compared with mRECIST-based progression-free survival. Pending prospective validation, ARTIMES could potentially facilitate a more reliable response evaluation in pleural mesothelioma. Wed, 17 Jun 2026 22:30:05 +0000
[Articles] Treatment-related adverse events of CD3-based T cell-engaging bispecific antibodies in patients with cancer: a meta-analysis of clinical trials The toxicity profile of T cell-engaging bispecific antibodies varies substantially across cancer types and antibody classes. This meta-analysis provides a comprehensive overview of treatment-related adverse event incidence and patterns, offering a valuable reference for optimising patient management in clinical practice. Fri, 12 Jun 2026 22:30:01 +0000
[Review] Novel strategies to overcome the blood–brain barrier in triple-negative breast cancer brain metastases Triple-negative breast cancer—the most aggressive breast cancer subtype—has a high propensity for brain metastases, with limited treatments and poor prognosis. The blood–brain barrier, long viewed as an impermeable therapeutic sanctuary, is the core barrier to effective care. This Review advocates a key paradigm shift for clinical and translational research: from merely circumventing the blood–brain barrier to actively targeting and exploiting its biology. We delineate triple-negative breast cancer-specific mechanisms of blood–brain barrier breach and evaluate emerging therapies via a clinically actionable three-pillar framework: physical and focal blood–brain barrier disruption, biological blood–brain barrier exploitation, and microenvironmental modulation. Wed, 01 Jul 2026 00:00:00 -0700
[Policy Review] European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine Imaging is central to diagnosing, staging, evaluating treatment response, and guiding post-therapy surveillance in osteosarcoma and Ewing sarcoma, yet no international consensus defines optimal modalities or schedules. This European guideline, developed by 36 multidisciplinary experts, seeks to standardise imaging for research and enhance patient care. A systematic review identified 2026 studies, of which 13 met criteria, revealing marked heterogeneity in diagnoses, chemotherapy regimens, and imaging protocols. Wed, 01 Jul 2026 00:00:00 -0700
[Policy Review] Reirradiation for recurrent head and neck squamous cell carcinoma: international expert consensus recommendations endorsed by the Reirradiation Collaborative Group, the European Society for Radiotherapy and Oncology Reirradiation Focus Group, and the American Society for Radiation Oncology Reirradiation can be considered for some patients with recurrent or second primary head and neck squamous cell carcinoma arising within previously irradiated regions, a clinical scenario associated with few therapeutic options. The increasing use of modern conformal radiotherapy techniques, including intensity-modulated radiotherapy, proton therapy, and stereotactic body radiotherapy, has expanded the feasibility of reirradiation in clinical practice. However, evidence remains heterogeneous, and clinical choices are challenged by substantial variability in patient presentation, previous treatments, and toxicity risk. Wed, 01 Jul 2026 00:00:00 -0700
|
Toward exercise as standard care for older cancer survivors
Fri, 03 Jul 2026 10:29:49 -0700 Maintenance therapy in gynecologic malignancies: Current and future state Fri, 03 Jul 2026 10:19:52 -0700 Long‐term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970–1999: A report from the Childhood Cancer Survivor Study No differences in late mortality, SMNs, and most CHCs were observed between patients who received VDC versus VDC/IE. Aging EWS survivors’ elevated risk of morbidity and mortality underscores the need for lifelong survivorship care and therapies that reduce the risk for late effects. Thu, 02 Jul 2026 08:40:00 -0700 Large‐scale osteosarcoma sequencing reveals age‐associated genomic architectures Thu, 02 Jul 2026 08:15:32 -0700 Issue Information Thu, 02 Jul 2026 07:59:26 -0700 |
||
|
| |||
|
[Editorial] Ebola outbreak: why haematology matters
As of June 3, WHO Director-General Tedros Ghebreyesus reported 344 confirmed cases of Ebola virus disease in DR Congo, as well as 15 confirmed cases in Uganda. Encouragingly, suspected cases in the DR Congo have fallen, as efforts continue to eliminate delays in testing. However, this outbreak, caused by Bundibugyo virus (Orthoebolavirus bundibugyoense), highlights a recurring vulnerability in epidemic preparedness: limited access to reliable and accurate diagnostics and absence of specific treatments and vaccines. Wed, 10 Jun 2026 22:30:01 +0000
[Comment] Apixaban for paediatric venous thromboembolism: cautious optimism For decades, paediatric anticoagulation has been guided more by extrapolation than by evidence. Treatments for venous thromboembolism in children have largely mirrored adult practice, despite fundamental developmental differences in haemostasis and drug handling. The emergence of direct oral anticoagulants (DOACs) marks a turning point, with the first generation of trials specifically designed for paediatric populations published in the past 5 years. Within this context, the study by Leonardo R Brandão and colleagues1 provides timely and important data on apixaban in children with venous thromboembolism. Wed, 01 Jul 2026 00:00:00 -0700
[Corrections] Correction to Lancet Haematol 2026; 13: e338–50 Edel Y, Stein PE, Kawtharany H, et al. Guidelines for the management of acute porphyria: recommendations from the International Porphyria Network. Lancet Haematol 2026; 13: e338–50—In this Review, the list of countries in the first paragraph of the Methods section should contain Norway and not Denmark. This change has been made on May 27, 2026. Wed, 27 May 2026 22:30:01 +0000
[Corrections] Correction to Lancet Haematol 2026; 13: e396–407 Donzel M, Khedimallah S, Barriere S, et al. Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study. Lancet Haematol 2026; 13: e396–407—In this Article, Agathe Gouband and Damien Luque Paz's affiliation should have been “Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, Angers, France”, and their degrees should have been PharmD. In addition, the acknowledgments should read “We thank the FIMBANK network, funded by the French Institut National du Cancer (INCa BCB 2013 & 2022), for providing data for some of the patients included in the present study.” These corrections have been made to the online version as of July 2, 2026. Wed, 01 Jul 2026 00:00:00 -0700
[In Focus] Essential but neglected: securing the global supply of human hyperimmune immunoglobulins In 2025, the European Medicines Agency and the Heads of Medicines Agencies issued recommendations to address vulnerabilities in the supply of anti-RhD immunoglobulin (RHIG; used to prevent RhD alloimmunisation during pregnancy). This alert highlights a broader but under-recognised problem: the fragile global supply of hyperimmune immunoglobulins, a group of plasma-derived medicines essential for post-exposure prophylaxis (PEP) and maternal–child health. Despite their various inclusions in the WHO Model Lists of Essential Medicines for adults and children and in national lists, these products remain vulnerable to shortages and fragmented procurement in both high-income countries (HICs) and low-income and middle-income countries (LMICs). Wed, 01 Jul 2026 00:00:00 -0700
[In Focus] Exhibition: sharing the history of blood through patients’ stories With its museums, art galleries, and a castle that dominates the skyline, it is little wonder that Edinburgh, UK, is ranked regularly among the most popular global destinations for tourists. Yet if visitors look beyond the most famous attractions—such as the Palace of Holyroodhouse, the Royal Yacht Britannia, and the Royal Botanic Garden—then Scotland's capital city boasts a plethora of destinations that lie off the beaten track. One of those hidden gems is the Physicians’ Gallery on Queen Street, a free museum in which the Royal College of Physicians of Edinburgh (RCPE) hosts exhibitions drawn from its library of more than 85 000 books, journals, pamphlets, and other items, supplemented with exhibits borrowed from other collections. Wed, 01 Jul 2026 00:00:00 -0700
[Articles] Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial Fixed-duration epcoritamab monotherapy showed promising complete response rates and a manageable safety profile in older adults with newly diagnosed DLBCL and comorbidities, with slight differences between stages 1 and 2. Continued investigation of epcoritamab as a first-line chemotherapy-free treatment option is warranted. Fri, 12 Jun 2026 22:30:01 +0000
[Articles] Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial Inotuzumab ozogamicin showed high activity as reinduction treatment in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse and a favourable toxicity profile with no treatment-related deaths. Tue, 16 Jun 2026 09:52:41 +0000
[Articles] Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study Our findings could assist clinicians in delivering more targeted and timely supportive care interventions and might inform patients about anticipated symptoms during the early post-CAR T-cell infusion period. Moreover, the observed discrepancies between patient-reported and clinician-reported symptoms suggest that more systematic use of patient-reported outcome measures might provide complementary insights beyond those captured through clinician assessment. Fri, 12 Jun 2026 22:30:01 +0000
[Articles] Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trial In this descriptive study, the safety and efficacy profile of a fixed-dose-by-bodyweight-tier apixaban regimen was similar to that of standard of care for the treatment of venous thromboembolism and prevention of venous thromboembolism recurrence in children younger than 18 years, providing a potential additional treatment option in this patient population. Wed, 01 Jul 2026 00:00:00 -0700
[Review] Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party The European Group for Blood and Bone Marrow transplantation Practice Harmonization and Guidelines Committee together with the Lymphoma Working Party convened 23 experts in Hodgkin lymphoma, transplantation, and radiation oncology, to develop consensus recommendations on the use of autologous and allogeneic haematopoietic cell transplantation (HCT) in relapsed or refractory Hodgkin lymphoma. Through a structured literature review and a 2-day workshop in Berlin, Germany, on Sept 29 and 30, 2025, the panel established guidance across major clinical decision points. Wed, 01 Jul 2026 00:00:00 -0700
[Review] Female reproductive health—what the classical haematologist needs to know Haematologists should be prepared to address several key transitions and timepoints during the female reproductive health lifespan to provide safe and equitable care for all patients with haematological disorders. In this Review, we summarise important points for recognition and consideration in the care of patients with lifelong or transient haematological conditions. We include discussions on menarche, pregnancy, menopause, and gender-affirming care, and how these life transitions might impact people with underlying haematological disorders, including an increased risk of iron deficiency with or without anaemia. Tue, 16 Jun 2026 22:30:02 +0000
[Viewpoint] A US perspective on optimising the inpatient classical haematology consultation service The inpatient classical haematology consult service occupies a specialised, complex, and high-acuity domain in the hospital setting. As three academic classical haematologists practicing primarily or exclusively as inpatient consultants in the US, we describe the wide spectrum of haematological disorders we manage in our practices and the rapidly expanding number and complexity of treatments we have to offer, therefore necessitating a substantial breadth and depth of diagnostic and therapeutic expertise to practice successfully in this setting. Wed, 01 Jul 2026 00:00:00 -0700
[Clinical Picture] Fulminant haemophagocytic lymphohistiocytosis revealing an unexpected bone marrow pathogen A 25-year-old construction worker with a history of marijuana and cocaine use presented with 3 months of weight loss, fever, night sweats, cough, and progressive dyspnoea. He was transferred to Hospital Alma Mater de Antioquia (Medellín, Colombia) on Nov 20, 2025, after developing haemodynamic instability and worsening hypoxaemia, despite treatment with broad-spectrum antibiotics. Imaging showed a left pleural effusion with lower-lobe atelectasis, generalised lymphadenopathy, and hepatosplenomegaly. Wed, 01 Jul 2026 00:00:00 -0700
|
A bone to pick with ferric carboxymaltose
Volume 148, Issue 1 July 2 2026 Genomics reboot for secondary myelofibrosis Volume 148, Issue 1 July 2 2026 EBV and immunodeficiency: the odd couple drawn to the brain Volume 148, Issue 1 July 2 2026 Is low a go for pediatric AML? Volume 148, Issue 1 July 2 2026 When the KAT’s away, vulnerability for AML comes out to play Volume 148, Issue 1 July 2 2026 A step toward streamlining HIT diagnosis Volume 148, Issue 1 July 2 2026 ELISA-negative HIT: antibody recognition and relevance Volume 148, Issue 1 July 2 2026 Identifying steroid-refractory aGVHD before it happens Volume 148, Issue 1 July 2 2026 Ferric carboxymaltose increases fracture risk in patients and reduces bone formation in mice with iron deficiency anemia The use of IV iron in clinical practice has increased significantly in recent years. In this Plenary Paper, Wagner and colleagues demonstrate that ferric carboxymaltose (FCM) is associated with a higher risk of fractures than ferric derisomaltose and show that FCM impairs bone recovery in mouse models despite correction of anemia. Mechanistically, FCM preferentially accumulates in bone, suppresses collagen production and bone formation pathways, alters dentin matrix protein 1–integrin signaling, and sustains elevated fibroblast growth factor 23 levels, suggesting that its skeletal toxicity extends beyond the well-recognized effects of hypophosphatemia. These findings support consideration of alternative IV iron formulations that provide similar efficacy without risk of skeletal complications.
Volume 148, Issue 1 July 2 2026 Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant Hairy cell leukemia (HCL) and HCL variant (HCLv) are uncommon chronic B-cell neoplasms that share several clinical and pathological features but differ substantially in their molecular drivers, clinical course, and therapeutic approach. Zent and colleagues present consensus guidelines that offer clinicians an updated overview of current approaches to diagnosing and managing patients with HCL and HCLv, along with perspectives on emerging targeted therapies aimed at improving outcomes.
Volume 148, Issue 1 July 2 2026 Genomic profiling for decision-making in post–polycythemia vera and post–essential thrombocythemia myelofibrosis Mora and colleagues have improved the existing myelofibrosis secondary to polycythemia vera and essential thrombocythemia prognostic model (MYSEC-PM) for secondary myelofibrosis by incorporating molecular and cytogenetic data, creating the mutation-enhanced MYSEC-mPM and the karyotype- and mutation-enhanced MYSEC-kmPM. By analyzing 644 patients, they identified mutations in ASXL1, U2AF1, TP53, and SRSF2, as well as complex or monosomal karyotypes, as independent predictors of poor survival, significantly improving risk stratification beyond clinical factors alone. These updated models provide more precise survival prediction that may better guide transplant decisions, patient monitoring, and clinical trial design.
Volume 148, Issue 1 July 2 2026 Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study Kaulen and colleagues from the International Primary CNS Lymphoma (PCNSL) Collaborative Group (IPCG) developed the IPCG ID-PCNSL prognostic score for immunodeficiency-associated PCNSL, demonstrating its ability to stratify outcomes across patients with HIV infection, solid organ transplantation, or autoimmune disorders. Their analysis highlights the biological and clinical distinctiveness of Epstein-Barr virus–driven PCNSL in immunocompromised patients, while showing that survival remains poor for high-risk groups despite widespread use of immune restoration strategies and rituximab- and high-dose methotrexate–based therapies. The study establishes the IPCG ID-PCNSL score as a practical tool for risk-adapted treatment decisions.
Volume 148, Issue 1 July 2 2026 Low- vs standard-dose regimens as induction for pediatric AML: a multicenter, randomized noninferiority trial Induction therapy for pediatric acute myeloid leukemia (AML) is highly intensive and carries significant risks of toxicity. Gao and colleagues report results from the phase 3 CALS III-AML18 trial, showing that low-dose induction chemotherapy with granulocyte colony-stimulating factor achieves remission rates and survival outcomes comparable to those with standard-dose induction therapy in children with AML. This low-dose regimen is associated with fewer toxicities, faster hematologic recovery, and reduced health care costs, suggesting a feasible treatment strategy for resource-limited settings. Further validation of this chemotherapy deescalation regimen is needed for optimization of low-dose approaches.
Volume 148, Issue 1 July 2 2026 Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML Lysine acetyltransferases (KATs) are chromatin modifiers that facilitate transcriptional activation. Meyerhöfer and colleagues demonstrate that pharmacologic inhibition of the KAT activity of p300/CREBBP unexpectedly activates interferon-stimulated genes in acute myeloid leukemia (AML) cells by increasing p300/CREBBP occupancy at interferon-responsive regulatory elements and promoting STAT1-mediated transcription. This transcriptional rewiring sensitized AML cells to interferon alpha, increased apoptosis, and reduced leukemia burden in both in vitro and in vivo models. Further preclinical evaluation is needed to understand the translational implications of these findings.
Volume 148, Issue 1 July 2 2026 Engineering single-chain variable fragments to identify pathogenic antibodies in heparin-induced thrombocytopenia One of the major challenges in heparin-induced thrombocytopenia (HIT) diagnosis is differentiating between pathogenic and nonpathogenic anti–heparin/platelet factor 4 (PF4) antibodies. Bissola and colleagues developed engineered single-chain variable fragment (scFv) inhibitors derived from a HIT-like monoclonal antibody to selectively target pathogenic heparin/PF4 antibody epitopes and improve diagnostic discrimination in HIT. The incorporation of these scFvs into enzyme immunoassays increased specificity and improved assay accuracy in a small patient cohort. Further analytical and clinical validation in larger cohorts is required before clinical implementation.
Volume 148, Issue 1 July 2 2026 Non-PF4/heparin-binding, platelet-activating antibodies in heparin-induced thrombocytopenia In this study, Zhou et al show that some platelet-activating anti–platelet factor 4 (PF4) antibodies in heparin-induced thrombocytopenia (HIT) are not detected by standard PF4/heparin enzyme-linked immunosorbent assays (ELISAs). These ELISA-negative antibodies can still strongly activate platelets through FcγRIIA-dependent mechanisms and contribute substantially to pathogenic activity, reflecting context-dependent antigen recognition of PF4 complexes. Although these findings highlight limitations of current immunoassays, ELISA-negative functional antibodies appear uncommon in routine practice, reinforcing the continued importance of integrating clinical scoring with both immunoassays and functional platelet activation testing.
Volume 148, Issue 1 July 2 2026 CD28+ CD8+ Tem cells with a STAT1-dependent glucocorticoid receptor deficit contribute to steroid-refractory acute GVHD Steroid-refractory acute graft-versus-host disease (aGvHD) remains a major clinical challenge after allogeneic hematopoietic stem cell transplantation. Pan and colleagues investigated biomarkers that identify patients with newly developed aGvHD destined to become steroid refractory. Expansion of activated CD28+ CD8+ effector-memory T (Tem) cells was associated with steroid-refractory disease and linked to a proinflammatory, STAT1-driven reduction in glucocorticoid receptor expression. They further show that JAK/STAT inhibition with ruxolitinib can reverse these changes and restore steroid sensitivity, suggesting a potential strategy for early or preemptive treatment of high-risk patients.
Volume 148, Issue 1 July 2 2026 Therapy-related AML with MECOM rearrangement, biallelic TP53 inactivation, and striking nuclear abnormalities Volume 148, Issue 1 July 2 2026 Bachmann PS, Piazza RG, Janes ME, et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood. 2010;116(16):3013-3022. Volume 148, Issue 1 July 2 2026 Chari A, van de Donk NWCJ, Dholaria B, et al. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. Blood. 2025;146(24):2902-2913. Volume 148, Issue 1 July 2 2026 |
High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1%
Fri, 03 Jul 2026 23:11:06 -0700 Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma Fri, 03 Jul 2026 23:06:36 -0700 Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children Fri, 03 Jul 2026 22:48:08 -0700 Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management Fri, 03 Jul 2026 21:09:53 -0700 Striking Bone Marrow Plasmacytosis Resulting From Visceral Leishmaniasis Fri, 03 Jul 2026 14:42:47 -0700 Massive Neutrophil Necrobiosis due to Colchicine Toxicity Fri, 03 Jul 2026 14:42:47 -0700 Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents Fri, 03 Jul 2026 14:42:47 -0700 Intensive Induction in AML in the Era of Venetoclax: A Standing Count for “7 + 3”? Fri, 03 Jul 2026 14:42:47 -0700 Issue Information Fri, 03 Jul 2026 14:42:47 -0700 Correction to “DNA Methylation Episignature as a Novel Diagnostic Tool for Diamond‐Blackfan Anemia Syndrome” Fri, 03 Jul 2026 14:42:47 -0700 The Role of the Gut Microbiota in Allogeneic Hematopoietic Cell Transplantation Fri, 03 Jul 2026 14:42:47 -0700 CAR T‐Cell Therapy in Patients With Primary Central Nervous System Lymphoma: A LOC Network Study Fri, 03 Jul 2026 14:42:47 -0700 Response to: “Refining Combined‐Modality Therapy and Charting the Future of Primary Vitreoretinal Lymphoma” Fri, 03 Jul 2026 14:42:47 -0700 Response to: “Refining Combined‐Modality Therapy and Charting the Future of Primary Vitreoretinal Lymphoma” Fri, 03 Jul 2026 14:42:47 -0700 Hydroxyurea Delays the Onset of Hyposplenism in Young Children With Sickle Cell Disease Fri, 03 Jul 2026 14:42:47 -0700 Common Threshold of Measurable Disease Improperly Excludes Patients With AL Amyloidosis From Clinical Trials Fri, 03 Jul 2026 14:42:47 -0700 Response to Methodological Concerns Regarding Eligibility Criteria and Study Selection in a Systematic Review and Meta‐Analysis of CAR T‐Cell Therapy for Hematologic Malignancies Fri, 03 Jul 2026 14:42:47 -0700 NGS‐Driven Digital PCR for Personalized and Accurate Measurable Residual Disease Assessment in Acute Myeloid Leukemia Fri, 03 Jul 2026 14:42:47 -0700 Prognostic Value of Hypoxemia for Acute Chest Syndrome in Adults With Sickle Cell Disease Fri, 03 Jul 2026 14:42:47 -0700 The Association of Age and Frailty With Adverse Events for Bortezomib and Carfilzomib: A Population‐Based Analysis Fri, 03 Jul 2026 14:42:47 -0700 Real‐World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman Disease Fri, 03 Jul 2026 14:42:47 -0700 |
|
|
| |||
|
Remission with residuals, but no cure June 23 2026 - Volume 10, Issue 12 Lights, camera, occlusion! watch sickle cells in real time June 23 2026 - Volume 10, Issue 12 Outsmarting NK surveillance: engineering stealth CAR T cells June 23 2026 - Volume 10, Issue 12 ASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism June 23 2026 - Volume 10, Issue 12 Invasive fungal infections after Bruton tyrosine kinase inhibitor treatment: a systematic review and meta-analysis June 23 2026 - Volume 10, Issue 12 Supportive care interventions in hematopoietic stem cell transplantation: a systematic review and meta-analysis June 23 2026 - Volume 10, Issue 12 Direct oral anticoagulants in portal vein thrombosis in patients with cirrhosis: a systematic review and meta-analysis June 23 2026 - Volume 10, Issue 12 BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study June 23 2026 - Volume 10, Issue 12 Quizartinib for patients with newly diagnosed FLT3-ITD–positive AML who received maintenance therapy in QuANTUM-First June 23 2026 - Volume 10, Issue 12 Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: a multicenter prospective study June 23 2026 - Volume 10, Issue 12 A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement June 23 2026 - Volume 10, Issue 12 An inpatient Serious Illness Care Program for older patients with hematologic malignancies: a single-arm pilot study June 23 2026 - Volume 10, Issue 12 Mining single-cell transcriptomic data reveals distinct T-cell population in pediatric B-ALL and AML at diagnosis June 23 2026 - Volume 10, Issue 12 HLA-E single-chain trimer shields gene-edited allogeneic CAR T cells from NK cell attack June 23 2026 - Volume 10, Issue 12 Adding induction intrathecal cytarabine in newly diagnosed CNS2 B-acute lymphoblastic leukemia does not improve outcomes June 23 2026 - Volume 10, Issue 12 LySeqST: a targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma June 23 2026 - Volume 10, Issue 12 DLK1 is a GATA1s-driven dependency and therapeutic target in Down syndrome–associated myeloid leukemia June 23 2026 - Volume 10, Issue 12 Sickle cell visualization in vivo in humans: microvascular occlusion formation and hemorheological indices June 23 2026 - Volume 10, Issue 12 PGC-1α agonism via oral administration of ZLN005 induces fetal hemoglobin and is antisickling in sickle mice June 23 2026 - Volume 10, Issue 12 Identification of missense variants in the C-domains of von Willebrand factor that cause gain-of-function–like activity June 23 2026 - Volume 10, Issue 12 Targeting erythroid cell–derived asparagine inhibits alloimmunization in sickle cell disease June 23 2026 - Volume 10, Issue 12 Endothelial activation and damage associated with steroid-refractory aGVHD are counteracted by ruxolitinib June 23 2026 - Volume 10, Issue 12 Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-cell acute lymphoblastic leukemia June 23 2026 - Volume 10, Issue 12 NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy June 23 2026 - Volume 10, Issue 12 Rapid germ line testing with hair root bulb-derived DNA for hereditary predisposition and inherited marrow failure states June 23 2026 - Volume 10, Issue 12 Performance and clinical utility of Spanish germ line genetic testing criteria for hematologic neoplasms predisposition June 23 2026 - Volume 10, Issue 12 Risk factor analysis of 115 children and adolescents with primary mediastinal B-cell lymphoma treated with DA-EPOCH-R June 23 2026 - Volume 10, Issue 12 Glofitamab monotherapy in patients with Richter transformation: safety and efficacy from a phase 1 study June 23 2026 - Volume 10, Issue 12 Immune disparities in the TME of EBV+ and EBV− BL: role of reactive oxygen species generation pathways and platelet activation June 23 2026 - Volume 10, Issue 12 Eligibility versus appropriateness in allogeneic HCT June 23 2026 - Volume 10, Issue 12 Update of germ line RUNX1 variant curation rules: version 3.1 June 23 2026 - Volume 10, Issue 12 Hockman A, Anuskiewicz S, Brennan E, et al. Efficacy of eculizumab discontinuation in atypical hemolytic uremic syndrome: a systematic review and meta-analysis. Blood Adv. 2025;9(23):6096-6107. June 23 2026 - Volume 10, Issue 12 Lust H, Schultz LM, Kwon S, et al. Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy. Blood Adv. 2025;9(11):2763-2772. June 23 2026 - Volume 10, Issue 12 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma
New England Journal of Medicine, Volume 395, Issue 1, Page 32-43, July 2, 2026.
Angiography-Derived Fractional Flow Reserve to Guide PCI New England Journal of Medicine, Volume 395, Issue 1, Page 9-19, July 2, 2026.
Advances in Multiple Sclerosis New England Journal of Medicine, Volume 395, Issue 1, Page 54-68, July 2, 2026.
Ianalumab plus Eltrombopag in Immune Thrombocytopenia New England Journal of Medicine, Volume 395, Issue 1, Page 104-104, July 2, 2026.
Somatic Genetic Rescue of Immunodeficiency in WHIM Syndrome New England Journal of Medicine, Volume 395, Issue 1, Page 96-98, July 2, 2026.
Correcting False Narratives — Indispensable Latino Contributions to U.S. Population Health New England Journal of Medicine, Volume 395, Issue 1, Page 90-95, July 2, 2026.
Redefining Physiology in the Cardiac Catheterization Laboratory New England Journal of Medicine, Volume 395, Issue 1, Page 83-85, July 2, 2026.
Trampoline Fracture New England Journal of Medicine, Volume 395, Issue 1, July 2, 2026.
Operative versus Nonoperative Management for Appendicitis New England Journal of Medicine, Volume 395, Issue 1, Page 86-89, July 2, 2026.
Declarations of Independence — Physicians and the U.S. Body Politic, 1776–2026 New England Journal of Medicine, Volume 395, Issue 1, Page 1-3, July 2, 2026.
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis New England Journal of Medicine, Ahead of Print.
Iptacopan in IgA Nephropathy — Final 24-Month Data New England Journal of Medicine, Ahead of Print.
Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock New England Journal of Medicine, Ahead of Print.
Azithromycin for Preschoolers with Wheezing in the Emergency Department New England Journal of Medicine, Ahead of Print.
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer New England Journal of Medicine, Ahead of Print.
Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer New England Journal of Medicine, Ahead of Print.
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer New England Journal of Medicine, Ahead of Print.
Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica New England Journal of Medicine, Ahead of Print.
Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy New England Journal of Medicine, Ahead of Print.
Conservative Oxygen for Unresponsive Patients after Cardiac Arrest New England Journal of Medicine, Ahead of Print.
Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease New England Journal of Medicine, Ahead of Print.
Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema New England Journal of Medicine, Ahead of Print.
Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus New England Journal of Medicine, Ahead of Print.
Bundibugyo Virus Disease in 2026 — Clinical and Public Health Responses New England Journal of Medicine, Ahead of Print.
Clinical Characteristics of Patients Infected with Bundibugyo Virus, DRC 2026 New England Journal of Medicine, Ahead of Print.
Sirolimus-Eluting Technology for the Treatment of Peripheral Artery Disease New England Journal of Medicine, Ahead of Print.
A Watershed Moment in the Perioperative Treatment of Prostate Cancer New England Journal of Medicine, Ahead of Print.
Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609. New England Journal of Medicine, Ahead of Print.
The Social Contract of Bundibugyo Ebola Isolation New England Journal of Medicine, Ahead of Print.
|
|
|
| |||
|
Intra-fractional Voxel-wise Anatomical Motion Tracking Guided by Multimodal Respiratory Surrogates in Radiotherapy: Framework Development and Multi-Center Validation
Intra-fractional respiratory motion management encounters trade-offs between target coverage, organ at risk (OAR) sparing, and treatment efficacy. Real-time tracking is promising but hindered by invasiveness risks, lack of global deformations, or inadaptability to irregular respiration. Currently respiratory modeling-based adaptive tracking may offer ideal solutions, but is limited by discrete clinical priors, highly-sparse observations, and complex motion variability. This study advances the constrained modeling toward a synergistic knowledge- and information-augmentation-driven paradigm (KIADP), thereby bridging sparse real-time observations with voxel-wise anatomical deformations.
Thu, 02 Jul 2026 00:00:00 -0700 Gastrointestinal Motility-Induced Interplay in Pancreas Proton Therapy: Motion Simulation and Dosimetric Impact To simulate motion and evaluate its dosimetric interplay from gastrointestinal (GI) motility in pancreas pencil-beam scanning (PBS) proton therapy, and to assess how fractionation and motility amplitude affect target coverage and organ-at-risk (OAR) doses.
Thu, 02 Jul 2026 00:00:00 -0700 Proton beam therapy in nonmetastatic rhabdomyosarcoma: Outcome, prognostic factors and the effect of timing of radiation therapy We report survival and disease-specific outcomes, prognostic factors, and impact of radiotherapy timing in patients with non-metastatic rhabdomyosarcoma (RMS) treated with definitive proton beam therapy (PBT) at a national UK centre.
Thu, 02 Jul 2026 00:00:00 -0700 Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single Institution Series Management of recurrent glioblastoma remains a major challenge, with no treatment shown to meaningfully prolong survival. Reirradiation may offer local control but is often constrained by concerns regarding dose to critical normal tissues. We evaluated clinical outcomes, toxicity, and cumulative dosimetric parameters in patients with recurrent glioblastoma treated with hypofractionated proton reirradiation.
Thu, 02 Jul 2026 00:00:00 -0700 Single Percussive Ventilation Breath-hold Imaging and Delivery in Lung Tumor Stereotactic Ablative Radiation Therapy: Initial Observations From a Prospective Clinical Trial Tumor motion during respiration presents a challenge in delivering high-precision stereotactic ablative radiation therapy (SABR) for lung cancer. While inspiratory breath-hold techniques can minimize motion, they are often limited by the patients’ ability to sustain prolonged breath-holds and the variability that comes with repeat breath-holds. We present the first-in-human demonstration of the feasibility and safety of percussive ventilation breath-hold (PVB) to eliminate the uncertainty of breath-hold reproducibility between confirmatory volumetric image guidance and delivery of lung tumor SABR by completing both within the same assisted breath-hold.
Thu, 02 Jul 2026 00:00:00 -0700 A Gaussian-based planning approach for robust dose-escalated stereotactic body proton therapy Proton plans are often very homogenous with minimal hotspots compared to the prescribed dose, which may not be ideal for ablative stereotactic body radiation therapy (SBRT). A treatment planning approach for stereotactic body proton therapy (SBPT) is proposed to match the characteristics of photon SBRT dose distributions, namely a Gaussian-shaped curve with high centralized doses in the gross tumor volume (GTV) and rapid dose falloff in healthy tissues.
Wed, 01 Jul 2026 00:00:00 -0700 Privacy-Preserving Virtual Contrast-enhanced MRI for Nasopharyngeal Carcinoma: A Multi-center Study Contrast-enhanced MRI imaging via administration of contrast agents is critical for diagnosis, staging, and treatment of nasopharyngeal carcinoma. However, gadolinium-based contrast agents can lead to severe adverse effects, especially in patients with compromised kidney function, necessitating a safer alternative for contrast enhancement. In this study, we aim to develop and assess the clinical feasibility of a federated learning model for synthesizing virtual contrast-enhanced MRI (VCE-MRI) images from contrast-free scans for patients with nasopharyngeal carcinoma (NPC).
Wed, 01 Jul 2026 00:00:00 -0700 Liver tumor motion and reconstructed doses in a clinical trial of respiratory gated proton therapy for hepatocellular carcinoma Pencil beam scanning proton therapy of hepatocellular carcinoma (HCC) may reduce the risk of radiation-induced liver disease compared to photon radiotherapy, but tumor motion and anatomical changes can distort the dose. This was investigated through daily reconstruction of the delivered dose in a clinical trial of gated HCC proton therapy.
Tue, 30 Jun 2026 00:00:00 -0700 Local sinonasal and regional nodal effects of lymph node irradiation in a pilot study of dogs with naturally occurring sinonasal tumors Head and neck cancer patients with high risks for regional metastasis receive radiation therapy targeted to their primary tumor and regional lymph nodes (RLN). RLN irradiation may alter cancer immunity. We investigate the impact of RLN irradiation in a pilot study of dogs with sinonasal tumors undergoing stereotactic body RT (SBRT). We hypothesized that RLN irradiation would reduce effector lymphocyte populations in the local microenvironment and RLNs following SBRT compared to dogs treated with SBRT targeted to the tumor alone.
Tue, 30 Jun 2026 00:00:00 -0700 Cardiac Substructure Dosimetry and Major Adverse Cardiac Events After Breast Radiotherapy: A 12-Year Cohort Study with NTCP Modeling : To identify cardiac substructure dosimetric predictors of major adverse cardiac events (MACE) following breast radiotherapy, and to develop a robust normal tissue complication probability (NTCP) model for personalized risk assessment using a cohort with over a decade of follow-up.
Mon, 29 Jun 2026 00:00:00 -0700 Cross-Institutional Validation of a novel LLM-Based Cardiac Event Extraction framework from Electronic Health Records Cardiac toxicity is a significant concern for cancer patients undergoing radiotherapy. The complexity of evaluating cardiac events, the time required to parse the Electronic Health Record (EHR), and the need for large datasets make cardiotoxicity studies time- and resource-intensive, limiting progress of cardio-oncology research. Large-language models (LLMs) have the potential to automatically identify cardiac events. This work aimed to develop and validate a novel LLM-based automated cardiac event identification framework using a two-institution dataset.
Sun, 28 Jun 2026 00:00:00 -0700 Predictors of Medical Debt Sent to Collections after Radiotherapy Patients undergoing radiotherapy (RT) often face substantial out of pocket costs (OOPC), putting patients at risk of going into debt. Unpaid medical debt sent to collections is a proxy for severe financial distress.
Sat, 27 Jun 2026 00:00:00 -0700 Radiobiological characterization of 60 keV quasi-monoenergetic convergent photons To characterize the biological effects of low-energy photons generated by a ∼60-keV quasi-monoenergetic focused convergent-beam system (patented X-ray converging lens) compared with orthovoltage and 6-MV clinical photon beams.
Fri, 26 Jun 2026 00:00:00 -0700 External Beam Radiotherapy Primes PDL1-Targeted Radionuclide Therapy in Preclinical Colorectal Cancer Model Colorectal cancer (CRC) remains one of the most prevalent and lethal malignancies worldwide. Although external beam radiotherapy (RT) plays a growing role in primary and metastatic CRC, dose escalation may remain limited due to the high dose received by neighboring organs which may cause toxicity. Targeted Radionuclide Therapy (TRT) selectively delivers cytotoxic radiation to tumor cells through a molecular vector that targets a specific protein overexpressed by cancer cells, and is linked to a therapeutic radionuclide.
Fri, 26 Jun 2026 00:00:00 -0700 What is the Impact of Treatment De-Escalation on Patient Reported Outcomes in Patients with T1-T2 Oropharyngeal Cancers? A Secondary Analysis of the ORATOR Studies This study evaluates the impact of treatment de-escalation from 70 Gy to 60 Gy on patient-reported outcomes (PROs) and toxicity for patients with T1-2 p16-positive oropharyngeal squamous cell carcinoma (OPSCC) treated with primary radiotherapy as part of the BLINDED-FOR-REVIEW trials.
Thu, 25 Jun 2026 00:00:00 -0700 No evidence for depletion of circulating lymphocyte populations in primary brain tumor patients receiving radiotherapy alone To investigate the impact of radiotherapy (RT) for brain tumors on circulating lymphocyte populations and understand this from a dosimetric perspective.
Thu, 18 Jun 2026 00:00:00 -0700 |
|||
|
| |||
|
Breast Cancer: Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease
On June 24, 2026, the U.S. Food and Drug Administration (FDA) approved palbociclib (Ibrance) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone receptor (HR)-positive, HER2-positive locally advanced or... Wednesday, June 24, 2026 1:00 PM Single-Fraction SBRT in Localized Prostate Cancer In a phase I/II trial reported in JAMA Oncology, Zilli et al found that single-fraction high-dose stereotactic body radiotherapy (SBRT) was associated with a high biochemical relapse–free survival rate in patients with localized prostate cancer. Paving New ROADS in the Treatment of Brain Metastases With Implanted Tile-Based Radiation Therapy Tile-based radiation therapy (TBRT) implanted at the time of resection outperformed standard postoperative stereotactic radiation therapy (SRT) in the phase III Radiation One and Done Study (ROADS), improving surgical bed control and overall survival while maintaining a comparable safety profile,... FDA Approves Immunotherapy to Reduce Chronic GVHD in Patients Undergoing Stem Cell Transplant On June 30, the U.S. Food and Drug Administration (FDA) approved allogeneic regulatory T-cell–based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative... Wednesday, July 1, 2026 11:08 AM Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma As reported in The Lancet Oncology by Siva et al, 5-year findings in a pooled analysis of the FASTRACK and FASTRACK II trials support evidence of maintained disease control with ultra-hypofractionated stereotactic ablative body radiotherapy (SABR) in patients with primary renal cell carcinoma... FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap) in combination with abiraterone and prednisone for the treatment of adults with PTEN-deficient metastatic androgen pathway modulation–naive or –sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic... Friday, June 12, 2026 4:47 PM ASCO Remembers Karnofsky Award Recipient Maura L. Gillison, MD, PhD, Pioneer in HPV-Associated Cancers Novel Risk Score Stratifies Major Bleeding Risks in Patients With VTE on DOACs A novel bleeding risk score provides clinically relevant stratification for major bleeding risk in patients with cancer-associated venous thromboembolism (VTE) who received direct oral anticoagulant (DOAC) therapy, according to findings published in JACC: CardioOncology. Tuesday, June 30, 2026 11:00 AM Long-Term Outcomes With SABR in Primary Kidney Cancer As reported in The Lancet Oncology by Siva et al, long-term outcomes of an Australian-Dutch phase II study (TROG 15.03 FASTRACK II) support the safety and local disease control seen with stereotactic ablative body radiotherapy (SABR) in patients with primary kidney cancer who did not undergo... MRI-Guided Radiotherapy in High-Grade Glioma In a single-center Canadian phase II trial (UNITED) reported in The Lancet Oncology, Detsky et al found that magnetic resonance imaging (MRI)-guided adaptation of radiotherapy allowed margin de-escalation and resulted in a low rate of marginal failure in patients with high-grade glioma. I Miss My Life AACR Cancer Disparities Progress Report: Mortality Rates Improve, But Care Inequities Persist The American Association for Cancer Research (AACR) released its Cancer Disparities Progress Report 2026 on June 24. The report features the unprecedented progress being made against cancer, including the ongoing decline in cancer death rates, which have decreased by 35% since 1991, translating to... Fertility Preservation Access Remains ‘Limited and Unequal’ for Many Girls and Young Women With Cancer A new Columbia University School of Nursing systematic review published by Algave et al in the journal Cancer reveals access to fertility preservation care remains limited and unequal for girls and young women with cancer. Monday, June 29, 2026 11:13 AM Adverse Events With CD3-Based T-Cell–Engaging Bispecific Antibody Treatment in Cancer In a meta-analysis reported in The Lancet Oncology, Zhu et al identified treatment-related adverse events associated with the use of CD3-based T-cell–engaging bispecific antibodies in patients with hematologic or solid cancers. Survey Results Show Patients Prefer Learning of a Diagnosis From Their Doctor Rather Than a Health Portal Most patients who receive a cancer diagnosis still prefer to learn of the diagnosis from their doctors rather than from reports uploaded to their online health portal, according to findings of a survey conducted at the University of Texas Southwestern Medical Center. Findings were published as a... Monday, June 29, 2026 11:45 AM Existing Cardioprotective Agents Provide Limited Benefits for Patients With Cancer Existing agents such as statins and beta-blockers showed cardioprotective properties in select subgroups, but more treatments are needed to protect against heart failure in patients receiving treatment for cancer, according to findings from a systematic review and meta-analysis presented at the... Wednesday, June 24, 2026 2:00 PM Doublet in Low-Risk Gestational Trophoblastic Tumors In a French phase I/II trial (TROPHAMET) reported in JAMA Oncology, You et al found that first-line avelumab plus methotrexate was associated with high efficacy in patients with low-risk gestational trophoblastic tumors. Ultra–High-Risk LBCL: Does High-Dose Methotrexate Reduce Rates of CNS Relapse? In an analysis reported in the Journal of Clinical Oncology, Wilson et al found that prophylactic high-dose methotrexate does not provide significant benefit in reducing central nervous system (CNS) relapse in patients with ultra–high-risk large B-cell lymphoma (LBCL). FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC On June 24, 2026, the U.S. Food and Drug Administration (FDA) approved the antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy) for two indications in adults with triple-negative breast cancer (TNBC). Wednesday, June 24, 2026 4:30 PM Changes in AI Mammogram Risk Scores Over Time May Help to Predict Future Breast Cancer Using artificial intelligence (AI), researchers found that image-based risk scores for breast cancer derived from screening mammograms evolve over time and differ between women who develop cancer and those who do not, opening the door to a new era of dynamic breast cancer risk assessment. The new... Thursday, June 25, 2026 10:55 AM Multi-Cancer Early Detection Test Evaluated in Real-World Asian Cohort A large real-world study conducted across six Asian countries suggests that a blood-based multi-cancer early detection (MCED) test may accurately identify multiple cancer types in routine clinical practice, including cancers for which no standard screening programs currently exist. The research was ... Subgroup Analysis of Inavolisib Regimen in Asian Patients With Advanced Breast Cancer Treatment with the PI3K inhibitor inavolisib in combination with palbociclib and fulvestrant produced substantial clinical benefits in Asian patients with PIK3CA-mutated, hormone receptor–positive (HR-positive), HER2-negative, endocrine-resistant advanced breast cancer, according to a subgroup... GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD A large retrospective cohort study found that GLP-1 receptor agonist use was associated with significantly lower 5-year rates of colorectal cancer among patients with inflammatory bowel disease (IBD). The research was highlighted in a media briefing ahead of the 2026 ASCO Breakthrough Meeting,... Chinese Study of HER2-Targeted Combination in Neoadjuvant Therapy for Locally Advanced Breast Cancer A HER2-targeted regimen produced high pathologic complete response rates before surgery in patients with locally advanced HER2-positive breast cancer, according to results from a single-arm phase II neoadjuvant trial conducted in China. The research was highlighted in a media briefing ahead of the... Impact of Early Palliative Care on Quality of Life in Patients With Breast Cancer in India Early integration of palliative, or supportive, care at the time of breast cancer diagnosis improved quality of life more than on-demand palliative care in a randomized trial of patients in India. The research was highlighted in a media briefing ahead of the 2026 ASCO Breakthrough Meeting, taking... Advanced Breast Cancer: Novel CDK4/6 Inhibitor Plus an Aromatase Inhibitor In an interim analysis of a Chinese phase III trial (FCN-437c-III201) reported in JAMA Oncology, Yuan et al found that the addition of the novel CDK4/6 inhibitor fovinaciclib to aromatase inhibitor therapy was associated with significant improvement in progression-free survival in the first-line... |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer
Perioperative chemoimmunotherapy, comprising platinum-doublet chemotherapy plus an anti-PD-(L)1 antibody, has become the standard-of-care approach for patients with resectable non-small-cell lung cancer without an actionable driver alteration. However, the development of this approach has thus far been largely empirical, with limited capacity for adaptation of treatment strategies to better meet the needs of individual patients. In this Review, the authors discuss the potential for improvements in the current approach to perioperative therapy, including de-escalation for those with a pathological complete response, the capacity of various baseline and/or dynamic biomarkers to optimize outcomes, and the potential for escalation in patients with early evidence of a lack of responsiveness in the perioperative setting. Tue, 30 Jun 2026 00:00:00 -0700 Patient value over patent value: the mandate for open-source oncology Modern oncology has built highly efficient pathways for patent-protected innovation, but no equivalent machinery for evaluating and developing promising off-patent therapeutics. Herein, we frame ‘open-source oncology’ as a parallel public-interest infrastructure to test, authorize and implement credible generic agents. Designed to translate ownerless evidence into standard-of-care treatments, this framework applies the same scientific seriousness devoted to proprietary drugs, decoupling clinical value from commercial ownership. Fri, 26 Jun 2026 00:00:00 -0700 Cancer burden and control in China: landscape, trends and challenges Over the past decades, cancer epidemiology trends have substantially shifted in China, with a rapid increase in incidence of cancers that are most common in high-income countries and a substantial decline in incidence of cancers historically prevalent in China. The authors of this Review provide an overview of cancer epidemiology in China, a major contributor to global cancer burden, and discuss national cancer control policies and targets. Fri, 19 Jun 2026 00:00:00 -0700 New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer The therapeutic landscape of platinum-resistant ovarian cancer is rapidly evolving, with recent phase III trials demonstrating, for the first time, meaningful overall survival improvements beyond bevacizumab-based therapy. Herein we discuss how trials such as MIRASOL and, more recently, ENGOT-ov65/KEYNOTE-B96 and GOG30173/ENGOT-ov72/ROSELLA have established new standards of care through distinct biologically driven therapies and outline the new challenges that these approaches expose. Wed, 17 Jun 2026 00:00:00 -0700 Antibody–drug conjugates in gynaecological cancers: opportunities and challenges Three antibody–drug conjugates (ADCs) are currently approved for previously treated gynaecological cancers: mirvetuximab soravtansine for folate receptor-α-positive ovarian cancer, trastuzumab deruxtecan for solid tumours expressing HER2 and tisotumab vedotin for cervical cancer (independent of tissue factor expression). The authors of this Review discuss current priorities in the clinical development of ADCs for gynaecological cancers, such as identifying novel targets, understanding mechanisms of resistance and sequencing strategies, and managing toxicities, highlighting key advances and future opportunities. Wed, 17 Jun 2026 00:00:00 -0700 Teclistamab monotherapy improves survival in RRMM Teclistamab monotherapy improves survival in RRMM Mon, 15 Jun 2026 00:00:00 -0700 Potential new standard of care for resectable gastro-oesophageal adenocarcinoma in Asia Potential new standard of care for resectable gastro-oesophageal adenocarcinoma in Asia Fri, 12 Jun 2026 00:00:00 -0700 Daraxonrasib effective in metastatic pancreatic ductal adenocarcinoma Daraxonrasib effective in metastatic pancreatic ductal adenocarcinoma Fri, 12 Jun 2026 00:00:00 -0700 |
|
|
| |||
|
Development of a prognostic prediction model incorporating KDM1B for esophageal squamous cell carcinoma: an integrated transcriptomic and functional analysis
Vol 17, No 3 (June 29, 2026): Early palliative care decision is associated with reduced end-of-life healthcare utilization in patients with esophageal and gastric cancer Vol 17, No 3 (June 29, 2026): Machine learning-based gastric cancer risk prediction in an asymptomatic screening population: a retrospective cohort study Vol 17, No 3 (June 29, 2026): Overexpression of TAZ is associated with downregulation of E-cadherin and indicates poor prognosis in gastric cancer: a clinicopathological study Vol 17, No 3 (June 29, 2026): Evaluating the prognostic value of cuproptosis-related genes and characterizing PDE3B’s role in gastric cancer: integrative bioinformatics analysis and experimental validation Vol 17, No 3 (June 29, 2026): p62/SQSTM1-TRAF6/RIP1 complexes activate NF-κB-mediated PD-L1 expression and promote T-cell apoptosis in MKN45 gastric cancer cells Vol 17, No 3 (June 29, 2026): Histopathologic, molecular, and clinical associations of fusion-positive gastrointestinal carcinomas Vol 17, No 3 (June 29, 2026): Comparison of endoscopic submucosal dissection and surgery for early signet-ring cell carcinoma of the stomach: a multicenter study Vol 17, No 3 (June 29, 2026): Metabolic profile alterations as early indicators of gastrointestinal stromal tumors (GISTs) recurrence and imatinib resistance Vol 17, No 3 (June 29, 2026): A nomogram for predicting progression-free survival in stage III–IV gastric cancer based on post-treatment cholinesterase and C-reactive protein Vol 17, No 3 (June 29, 2026): Efficacy and safety of modified FLOT chemotherapy in gastric or gastroesophageal junction adenocarcinoma: a retrospective cohort study Vol 17, No 3 (June 29, 2026): Excess late mortality among long-term gastric cancer survivors following gastrectomy: a population-based cohort study Vol 17, No 3 (June 29, 2026): Tumor growth suppression of ivermectin in gastric cancer cell lines and primary gastric cancer organoids Vol 17, No 3 (June 29, 2026): A prognostic nomogram based on log odds of positive lymph nodes to predict survival in gastric cancer patients with neoadjuvant chemotherapy: a large population-based cohort study and external validation Vol 17, No 3 (June 29, 2026): Rising prevalence of venous thromboembolism in gastrointestinal cancers: a nationwide analysis of 205 million hospitalizations, 2016–2022 Vol 17, No 3 (June 29, 2026): Comparison of preoperative urinary Titin levels and serum Titin levels in patients with gastrointestinal malignancy Vol 17, No 3 (June 29, 2026): Independent prognostic value of tumor deposits in stage III colorectal cancer: a large-scale systematic review and meta-analysis Vol 17, No 3 (June 29, 2026): SOX18 knockdown inhibits colorectal cancer metastasis and angiogenesis through regulation of SAPK/JNK and PI3K/AKT/mTOR signaling pathways Vol 17, No 3 (June 29, 2026): Nursing-led enhanced recovery bundled care in colorectal cancer surgery: a systematic review and meta-analysis Vol 17, No 3 (June 29, 2026): Association of the global inflammatory-nutritional index (GINI) with time to next treatment and overall survival in patients with metastatic colorectal cancer receiving third-line therapy: a real-world retrospective study Vol 17, No 3 (June 29, 2026): Paeoniflorin inhibits colorectal cancer stem cell properties via regulating LINC01711/KMT2D/KLF7 axis Vol 17, No 3 (June 29, 2026): Development of a multivariable prediction model for tumor response and treatment tolerance based on body composition dynamics in rectal cancer undergoing neoadjuvant chemoradiotherapy Vol 17, No 3 (June 29, 2026): Younger age at colorectal cancer diagnosis in hereditary gastrointestinal cancer predisposition syndromes and Lynch syndrome: a nationwide analysis Vol 17, No 3 (June 29, 2026): Integrating network pharmacology, molecular docking, and experimental verification to investigate the mechanism of baicalein in colorectal cancer Vol 17, No 3 (June 29, 2026): Deep learning model based on MRI-derived microvascular network simulation parameters for noninvasive assessment of lymphovascular invasion in rectal cancer patients Vol 17, No 3 (June 29, 2026): Identification of telomere-related genes in the progression of colon adenocarcinoma: a bioinformatics analysis Vol 17, No 3 (June 29, 2026): Colorectal cancer survival in patients without curative measures: a retrospective cohort study Vol 17, No 3 (June 29, 2026): Association between preoperative aspartate aminotransferase-to-platelet ratio index and prognosis in colorectal liver metastases: a systematic review and meta-analysis Vol 17, No 3 (June 29, 2026): Transanal drainage tube versus diverting stoma for reducing anastomotic leakage after rectal cancer surgery: a systematic review and meta-analysis Vol 17, No 3 (June 29, 2026): Identification and preliminary examination of prognostic genes linked to calcium metabolism in colorectal cancer Vol 17, No 3 (June 29, 2026): Clinicopathological and molecular profiling of sporadic synchronous multiple primary colorectal cancers: focus on microsatellite instability status Vol 17, No 3 (June 29, 2026): Single-cell transcriptomics reveals the prognostic and immune infiltration significance of FOLFOX-bevacizumab treatment and lysine crotonylation characteristics in colon cancer Vol 17, No 3 (June 29, 2026): Prognostic and therapeutic significance of microscopic tumor focus in combined hepatocellular-cholangiocarcinoma: a multicenter pathological study Vol 17, No 3 (June 29, 2026): Sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs as a potential approach for advanced hepatocellular carcinoma with portal vein tumor thrombus: a prospective study Vol 17, No 3 (June 29, 2026): A retrospective study on the outcomes of yttrium-90 radiation segmentectomy with resin microspheres compared to microwave ablation for early primary hepatocellular carcinoma Vol 17, No 3 (June 29, 2026): The impact of adjuvant chemotherapy on overall survival and cancer-specific survival in patients with extrahepatic cholangiocarcinoma across different age groups: a population-based study Vol 17, No 3 (June 29, 2026): Mining and experimental validation of machine learning-based immune-related diagnostic biomarkers for hepatocellular carcinoma Vol 17, No 3 (June 29, 2026): The role of number-of-excitations (NEX) for the usability of free-breathing acquired diffusion-derived ‘vessel density’ (DDVD) and slow diffusion coefficient (SDC) maps in separating liver cysts, hemangiomas, and solid masses with a focus on small lesions Vol 17, No 3 (June 29, 2026): Identification and functional validation of SPON2 as a novel biomarker for the diagnosis and prognosis in hepatocellular carcinoma Vol 17, No 3 (June 29, 2026): A nomogram‑based diagnostic prediction model for differentiating mucinous cystic neoplasms from simple hepatic cysts in patients with hepatic cystic lesions Vol 17, No 3 (June 29, 2026): Global burden landscape (1990–2021) of gallbladder and biliary tract cancer attributable to high body mass index in older adults and a projection to 2050 Vol 17, No 3 (June 29, 2026): Real-world feasibility and safety of neoadjuvant FOLFIRINOX in pancreatic ductal adenocarcinoma: a retrospective single-center study Vol 17, No 3 (June 29, 2026): A single-cell and machine learning framework identifies CAFs-associated signatures linking stromal heterogeneity to immune regulation in pancreatic cancer Vol 17, No 3 (June 29, 2026): Prognostic value of lactate dehydrogenase-to-albumin ratio in metastatic/recurrent pancreatic cancer treated with first-line gemcitabine plus nab-paclitaxel: a single-center retrospective cohort study Vol 17, No 3 (June 29, 2026): Hepatocellular carcinoma metastasis to salivary glands: a systematic review of diagnostic challenges and survival outcomes Vol 17, No 3 (June 29, 2026): Deciphering the tubulin code: roles and mechanisms of microtubule post-translational modifications in gastrointestinal tumors: a narrative review Vol 17, No 3 (June 29, 2026): From metabolic dysregulation to malignancy: the presence of ZPR1 in gastrointestinal and hepatopancreatobiliary malignancies Vol 17, No 3 (June 29, 2026): A case report of diffuse large B-cell lymphoma and gastric signet ring cell adenocarcinoma in the same anatomic site: a clinical and management conundrum Vol 17, No 3 (June 29, 2026): Solid pseudopapillary neoplasm of the pancreas with postoperative multiple liver metastases in an older woman: a case report Vol 17, No 3 (June 29, 2026): Patterns of KRAS, NRAS, and BRAF mutations in colorectal cancer in Chile: a 3-year real-world evidence [2019–2021]—a brief report Vol 17, No 3 (June 29, 2026): Th1–2 immune balance revisited: refining prognostic immune signatures in colorectal cancer Vol 17, No 3 (June 29, 2026): Interpreting ctDNA dynamics in gastrointestinal stromal tumor (GIST) therapy—timing may be key Vol 17, No 3 (June 29, 2026): Revisiting prognostic biomarkers in gastrointestinal stromal tumor: the potential role of ETV1 polymorphisms Vol 17, No 3 (June 29, 2026): Pancreatic ductal adenocarcinoma and edema: reassessing cachexia markers Vol 17, No 3 (June 29, 2026): Preoperative resting heart rate and colorectal cancer mortality: a robust association, but causality remains unestablished Vol 17, No 3 (June 29, 2026): Predicting adherence of imatinib in gastrointestinal stromal tumor—rise of the machines! Vol 17, No 3 (June 29, 2026): Natural product-based nanoengineering in gastrointestinal stromal tumors: early promise and translational challenges Vol 17, No 3 (June 29, 2026): Defining the role of endoscopic resection for esophageal gastrointestinal stromal tumors Vol 17, No 3 (June 29, 2026): Is the time of ethanol injection over?—has endoscopic ultrasonography-guided radiofrequency ablation become the preferred approach for small pancreatic neuroendocrine tumors? Vol 17, No 3 (June 29, 2026): Comparison of nomograms and predictive tools in gastrointestinal stromal tumor Vol 17, No 3 (June 29, 2026): Going beyond total skeletal muscle area at L3 (tSMA) to accurately assess pancreatic cancer cachexia Vol 17, No 3 (June 29, 2026): Association between surgical timing and postoperative outcome in patients with residual esophageal cancer after neoadjuvant chemoradiotherapy Vol 17, No 3 (June 29, 2026): T-helper 1 and 2 cell densities, and mesenteric cytokine levels, are prognostic markers in colorectal cancer Vol 17, No 3 (June 29, 2026): Endoscopic resection for esophageal gastrointestinal stromal tumor: feasibility and oncologic limits Vol 17, No 3 (June 29, 2026): ESOPEC: targeting micro-metastatic disease combined with local control Vol 17, No 3 (June 29, 2026): Linking deubiquitination to pyroptosis: new perspectives from OTUB1 in hepatocellular carcinoma Vol 17, No 3 (June 29, 2026): Challenges identified from trends in mortality among patients with gastrointestinal cancer in the United States Vol 17, No 3 (June 29, 2026): A transcriptomic five-gene signature for sorafenib response prediction in hepatocellular carcinoma: clinical promise and limitations Vol 17, No 3 (June 29, 2026): From prediction to judgment: what a five-variable nomogram teaches us about hepatocellular carcinoma Vol 17, No 3 (June 29, 2026): Shifting from static to dynamic: the prognostic value of the surgical stress response in hepatocellular carcinoma Vol 17, No 3 (June 29, 2026): Ranking targeted therapies in advanced pancreatic adenocarcinoma: insights from a network meta-analysis Vol 17, No 3 (June 29, 2026): A hub for an herb: is STAT3 blockade at the epicenter of toosendanin-induced NCOA4-dependent ferritinophagy and ferroptosis in cancer cells? Vol 17, No 3 (June 29, 2026): Retraction: Promotion of perineural invasion of cholangiocarcinoma by Schwann cells via nerve growth factor Vol 17, No 3 (June 29, 2026): |
ASO Visual Abstract: Revisiting the Concept of Nerve-Sparing Radical Hysterectomy: A Proof-of-Concept Prospective Study from a Cervical Cancer Cohort
Tue, 30 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Sentinel Node Biopsy in the Neck Management of cN0 Sinonasal Squamous Cell Carcinoma—A Multicenter Pilot Trial on Safety and Feasibility Tue, 30 Jun 2026 00:00:00 -0700 ASO Visual Abstract: High Prevalence of Clinical Understaging in Early Gastric Cancer: An Analysis of the NCDB Tue, 30 Jun 2026 00:00:00 -0700 The Role of Surgery on the Treatment of Primary Pulmonary Sarcomas and Pulmonary Sarcomatoid Carcinoma Tue, 30 Jun 2026 00:00:00 -0700 ASO Author Reflections: Expanding the Boundaries of ICG-Guided Anatomical Liver Resection: The “Jigsaw-Pattern” Positive Staining Technique Mon, 29 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Factors Associated with Omission of Axillary Lymph Node Dissection for Patients with Clinical Node-Positive Breast Cancer who have Residual Nodal Disease on Pathology After Neoadjuvant Chemotherapy Mon, 29 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Association Between Axillary Surgical Management and Survival in Patients with de novo Metastatic Breast Cancer Mon, 29 Jun 2026 00:00:00 -0700 ASO Author Reflections: Looking Beyond Imaging—Multimodal Response Assessment after Modern Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma Mon, 29 Jun 2026 00:00:00 -0700 ASO Author Reflections: From Fundamentals to Innovation: The Evolution of Minimally Invasive Right Hepatectomy Mon, 29 Jun 2026 00:00:00 -0700 ASO Author Reflections: Quantifying the Unseen: Years of Life Lost as a Patient-Centered Metric in Advanced Bladder Cancer Mon, 29 Jun 2026 00:00:00 -0700 Reconsidering the Value of Lymphadenectomy in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Immunotherapy: Insights from a Multicenter Retrospective Study Mon, 29 Jun 2026 00:00:00 -0700 Robotic Transmesocolic Approach to the Left Retroperitoneum Mon, 29 Jun 2026 00:00:00 -0700 Intraoperative Radiotherapy for Breast Cancer: Long-Term Experience Mon, 29 Jun 2026 00:00:00 -0700 Correlations Between the Histologic Growth Patterns of Peritoneal and Liver Metastases From Colorectal Cancer Mon, 29 Jun 2026 00:00:00 -0700 Is R1 Extended Liver Resection for Locally Advanced Intrahepatic Cholangiocarcinoma Justified? Nodal Status Not Margin Drives Prognosis Mon, 29 Jun 2026 00:00:00 -0700 Risk Stratification of Atypical Breast Lesions Diagnosed on Core Needle Biopsy: Toward Selective Surgical Excision Mon, 29 Jun 2026 00:00:00 -0700 Long-term Outcomes of Surgery for Clinical T4 Non-Small Cell Lung Cancer: Implications for Surgical Decision Making in the TNM 9th Edition Era Mon, 29 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Longitudinal Symptom Recovery After Pancreatectomy—A Prospective Patient-Reported Outcomes Study using MDASI Sat, 27 Jun 2026 00:00:00 -0700 ASO Author Reflections: Biological Limitations of ctDNA Surveillance in Colon Cancer: The Peritoneal Conundrum Sat, 27 Jun 2026 00:00:00 -0700 ASO Author Reflections: Preoperative Clues to Complex Surgery After Neoadjuvant Immunochemotherapy in Non-Small-Cell Lung Cancer Sat, 27 Jun 2026 00:00:00 -0700 ASO Author Reflections: Beyond Sarcopenia: A CT-Defined Frailty Phenotype in Esophageal Cancer Surgery Sat, 27 Jun 2026 00:00:00 -0700 Selective Organ Site Strategy Versus Debulking in Multiorgan Metastatic Colorectal Cancer: Lessons from the ORCHESTRA Trial Sat, 27 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Neuron-Associated Transcriptional Enrichment Is Associated with Distinct Biological States and Predicts Poor Prognosis in Gastric Cancer Sat, 27 Jun 2026 00:00:00 -0700 ASO Author Reflections: Tailored Robotic Transmesocolic Approach for Left Retroperitoneal Lesions Sat, 27 Jun 2026 00:00:00 -0700 ASO Author Reflections: Utilizing Traditional Wire and Wireless Methods in Bracketed Localization for Partial Mastectomies Sat, 27 Jun 2026 00:00:00 -0700 ASO Author Reflections: Neoadjuvant Therapy and Post-Recurrence Overall Survival in Intrahepatic Cholangiocarcinoma Sat, 27 Jun 2026 00:00:00 -0700 Global Disparities in Insurance Coverage of Post-Mastectomy Breast Reconstruction Sat, 27 Jun 2026 00:00:00 -0700 Risk Factors for Anastomotic Leaks in Simultaneous Resection of Primary Colon Cancer with Synchronous Liver Metastasis: A NSQIP Study Sat, 27 Jun 2026 00:00:00 -0700 Cyclin E1 Expression Predicts Poorer Outcome in HER2-positive Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy Sat, 27 Jun 2026 00:00:00 -0700 The Effect of Neoadjuvant Therapy on Post-Recurrence Overall Survival After Curative Resection for Intrahepatic Cholangiocarcinoma Sat, 27 Jun 2026 00:00:00 -0700 Tele-Expert Consultation for Locally Recurrent Rectal Cancer: A Prospective Multicenter Evaluation of the CONNECT-LR System Sat, 27 Jun 2026 00:00:00 -0700 A Prospective Multicenter Comparative Cohort Study of Neoadjuvant Sintilimab Plus Chemotherapy and Chemoradiotherapy in Resectable Clinical Node-Positive Esophageal Squamous Cell Carcinoma Sat, 27 Jun 2026 00:00:00 -0700 Development and Validation of a Novel Pathologic Nodal Staging System for Oral Squamous Cell Carcinoma After Neoadjuvant Immunochemotherapy Sat, 27 Jun 2026 00:00:00 -0700 SIGLEC12 Predicts Prognosis and Chemotherapeutic Vulnerability in Patients with Pancreatic Cancer Sat, 27 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Comparing Resident Team Performance in Complex Surgical Oncology: A Single-Institution Cohort Study Fri, 26 Jun 2026 00:00:00 -0700 ASO Author Reflections: Beyond the Sentinel Node—Identifying Whom to Spare Completion Axillary Dissection in the RxPONDER and MonarchE Era Fri, 26 Jun 2026 00:00:00 -0700 Global Trends in Surgical Oncology Deescalation Phase III Randomized Trials Fri, 26 Jun 2026 00:00:00 -0700 Invited Editorial about Article: “Salvage Metastasectomy after Adoptive Cell Transfer for Melanoma: Long-Term Updates” by Dinerman, Aaron et al. Fri, 26 Jun 2026 00:00:00 -0700 ASO Author Reflections: Beyond the View Count: Source Credibility as the True Determinant of Quality in Online Esophageal Cancer Information Fri, 26 Jun 2026 00:00:00 -0700 Implementing Paradigm Shifting Clinical Trials: Real-World Outcomes of Neoadjuvant Versus Adjuvant Immune Checkpoint Inhibitors in Advanced Melanoma Patients Fri, 26 Jun 2026 00:00:00 -0700 Long-term Outcomes After Resection of Solitary Colorectal Liver Metastases Fri, 26 Jun 2026 00:00:00 -0700 Factors Associated with Omission of Axillary Lymph Node Dissection for Patients with Clinical Node-Positive Breast Cancer Who have Residual Nodal Disease on Pathology After Neoadjuvant Chemotherapy Fri, 26 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Assessing Response and Outcomes to Modern Multi-Agent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma Thu, 25 Jun 2026 00:00:00 -0700 ASO Visual Abstract: A Single-Institution Comparative Analysis of Bracketed Localization for Partial Mastectomy Using Traditional Wire and Wireless Methods Thu, 25 Jun 2026 00:00:00 -0700 ASO Author Reflections: Distal Resection Margin Collagen Score to Predict Major Low Anterior Resection Syndrome After Neoadjuvant Chemoradiotherapy in Rectal Cancer Thu, 25 Jun 2026 00:00:00 -0700 ASO Author Reflections: Defining Patient-Reported Symptom Recovery After Pancreatectomy Thu, 25 Jun 2026 00:00:00 -0700 Association of Preoperative Ultrasound-Measured Tumor Proximity to Trachea and Posterior Capsule with Tracheal and RLN Invasion in Papillary Thyroid Microcarcinoma Thu, 25 Jun 2026 00:00:00 -0700 ASO Author Reflections: Beyond the Limits of Classic Hepatectomies: Ultrasound-Guided Parenchyma-Sparing Liver Resections Wed, 24 Jun 2026 00:00:00 -0700 Impact of Next-Generation Sequencing on Surgical Decision-Making in Branch-Duct IPMN Wed, 24 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Peritoneal Metastases in Stage II–III Colon Cancer Represent a Blind Spot for Circulating Tumor DNA Surveillance Tue, 23 Jun 2026 00:00:00 -0700 |
||
|
| |||
|
Rapid Evaluation of Artificial Intelligence Technology Used for Ambient Dictation in Primary Care: Comparing the Quality of Documentation of Artificial Intelligence–Generated and Human-Produced Clinical Notes
Annals of Internal Medicine, Volume 179, Issue 6, Page 765-772, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Effectiveness of Nonpharmacologic Treatments for Chronic Low Back Pain Annals of Internal Medicine, Volume 179, Issue 6, Page 773-784, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Low-Volume Polyethylene Glycol for Bowel Preparation in Hospitalized Adults Annals of Internal Medicine, Volume 179, Issue 6, Page 785-793, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Initiation of Medications for Alcohol Use Disorder Among Hospitalized Veterans Annals of Internal Medicine, Volume 179, Issue 6, Page 794-803, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Twenty-Three–Year Benefits of Sigmoidoscopy Screening for Colorectal Cancer Annals of Internal Medicine, Volume 179, Issue 6, Page 804-811, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Proximal Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea in the OSPREY Study Annals of Internal Medicine, Volume 179, Issue 6, Page 812-822, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Effectiveness and Tolerability of Pharmacologic Prophylaxis for Chronic Migraine Annals of Internal Medicine, Volume 179, Issue 6, Page 823-834, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Guidance Statement From the American College of Physicians (Version 2) Annals of Internal Medicine, Volume 179, Issue 6, Page 842-856, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 How Would You Manage This Patient With Iron Deficiency Anemia? Grand Rounds Discussion From Beth Israel Deaconess Medical Center Annals of Internal Medicine, Volume 179, Issue 6, Page 857-867, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Core Performance Measures for Migraine Headache: A Review by the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 6, Page 835-838, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Reforming 340B to Promote Program Integrity and Better Serve Vulnerable Populations: An American College of Physicians Policy Brief Annals of Internal Medicine, Volume 179, Issue 6, Page 839-841, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 “Never More Than 15 Feet From the Respirator”: Housestaff Research During the 1955 Boston Polio Epidemic Annals of Internal Medicine, Volume 179, Issue 6, Page 868-873, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Integrating Planetary Health in Health Guidelines (GRADE Guidance 46) Annals of Internal Medicine, Volume 179, Issue 6, Page 874-884, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 The Importance of the Childhood Immunization Schedule for Internal Medicine Annals of Internal Medicine, Volume 179, Issue 6, Page 885-888, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Reframing Social Drivers of Health in Patient Quality and Safety Annals of Internal Medicine, Volume 179, Issue 6, Page 889-891, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Automatic Tenure-Clock Extensions as a Safeguard Against Defunding Annals of Internal Medicine, Volume 179, Issue 6, Page 892-894, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 What FDA Clearance Does, and Does Not, Mean for Artificial Intelligence Annals of Internal Medicine, Volume 179, Issue 6, Page 895-897, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Redefining Documentation Quality in the Age of Ambient Artificial Intelligence Scribes Annals of Internal Medicine, Volume 179, Issue 6, Page 898-899, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Incorporating Planetary Health Into Clinical Guideline Decisions Annals of Internal Medicine, Volume 179, Issue 6, Page 900-901, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 A Kite Without a String Annals of Internal Medicine, Volume 179, Issue 6, Page 902, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Cleo Annals of Internal Medicine, Volume 179, Issue 6, Page 903-904, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 All the Way Down Annals of Internal Medicine, Volume 179, Issue 6, Page 905-906, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Risk-Guided Antihypertensive Treatment Eligibility in Older Adults Under Updated Hypertension Guidelines Annals of Internal Medicine, Volume 179, Issue 6, Page 908-911, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Amputation Rates Among Opioid-Related Hospitalizations in the United States, 2016 to 2022 Annals of Internal Medicine, Volume 179, Issue 6, Page 911-914, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 The Effect of 4:3 Intermittent Fasting on Weight Loss at 12 Months Annals of Internal Medicine, Volume 179, Issue 6, Page 915-916, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Dollars Needed to Pay per Early-Detected Colorectal Cancer Case in Stool-Based Screening Annals of Internal Medicine, Volume 179, Issue 6, Page 914, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
|
| |||
|
Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes
With the failure in chronic spontaneous urticaria, Evommune’s story is now centered on its anti-IL-18 therapy EVO301, Oppenheimer said, which in February elicited a 33% placebo-adjusted improvement in eczema severity.
Skyhawk CEO hopes FDA’s new uniQure position will translate to Huntington’s pill A recent FDA reversal sparked new hope for patients with Huntington’s disease. Flying under the radar, Skyhawk Therapeutics revealed 12-month functional data from a midstage trial of its own candidate showing improvements on a key disease measurement scale.
4 ovarian cancer candidates to watch: GSK, Allarity and more Recent approvals for Corcept Therapeutics and Merck have injected momentum into the space, where GSK, Allarity Therapeutics, OSE Immunotherapies and others are advancing their own candidates.
Revolution’s second RAS blocker doubles chemo response rate in pancreatic cancer Encouraging data for combination regimens of Revolution Medicines’ zoldonrasib “reinforce the path to leadership in PDAC” for the biotech, according to Truist Securities.
UniQure’s chronic epilepsy gene therapy ‘should be on investors’ radar’ As uniQure prepares its closely watched Huntington’s disease gene therapy for FDA review, the biotech is also making waves in chronic epilepsy with another gene therapy that Stifel says is off to a “promising start.”
New biotech cAMPfield emerges with $180M to reshape IBD treatment Backed by institutional investors and seasoned industry leaders, cAMPfield Therapeutics is advancing a clinical program aimed at reshaping the landscape for inflammatory bowel disease.
Verastem deprioritizes pancreatic cancer work after ‘decent, but not great’ data shadowed by Revolution Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug combo, instead putting resources behind its KRAS inhibitor pill for solid tumors.
Mirum, Incyte bolster case for approval in rare bone disease despite mid-stage miss While falling short of statistical significance, Incyte and Mirum Pharmaceuticals’ ALK2 inhibitor showed a “clear benefit” in reducing abnormal bone formation in a Phase 2 study of fibrodysplasia ossificans progressiva.
Elicio crashes on midstage pancreatic cancer miss but will advance to Phase 3 Elicio Therapeutics’ investigational cancer immunotherapy failed to meet the primary endpoint of disease-free survival in a Phase 2 trial—a result the company attributed mostly to a disproportionate number of patients with higher residual disease.
Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease Rhythm Pharmaceuticals’ Imcivree reduced fat—while boosting muscle—in patients with Prader-Willi syndrome.
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 Treos Bio Presents New Translational Data Showing PolyPEPI1018 Plus Anti-PD-L1 Immunotherapy Remodels the Tumor Immune Microenvironment in MSS Colorectal Cancer Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia AOB Pharma and Biorasi to Partner to run Phase 2b in Moderate to Severe Acne 60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease Aspen Neuroscience Announces Completion of Cohort 3 and 4 Dosing in Aspiro Phase 1/2a Trial of Sasineprocel for Parkinson’s Disease OTR4132 in patients with ischemic stroke meets primary efficacy endpoint OS Therapies Provides U.S. Regulatory Update Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program TolerogenixX Completes Last Patient Transplant in Phase IIb TOL-2 Trial of MIC-Lx, Advancing a New Immune Tolerance Approach in Kidney Transplantation |
Vistagen in freefall as social anxiety drug fails Phase 3
Despite the late-stage fail, Vistagen will nevertheless continue to push its drug candidate forward and meet with the FDA to align on a potential registrational path.
BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit BridgeBio Pharma plans to file for approval in the third quarter. If granted, the oral drug could present a “highly differentiated” option over current achondroplasia therapies, according to Jefferies.
4 ovarian cancer candidates to watch: GSK, Allarity and more Recent approvals for Corcept Therapeutics and Merck have injected momentum into the space, where GSK, Allarity Therapeutics, OSE Immunotherapies and others are advancing their own candidates.
Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears The positive ADHD data for Otsuka Pharmaceutical’s centanafadine is good news in what has of late been a mixed bag for the neuropsychiatric space.
Merck posts ‘encouraging’ Phase 3 ulcerative colitis data but Roche challenge looms Given its intravenous route of administration, Merck’s tulisokibart will likely “need to be meaningfully improved” over Roche’s afimkibart, which can be given subcutaneously, BMO Capital Markets analysts said. Both assets are being tested for ulcerative colitis.
Pfizer delivers ‘disappointing’ late-stage lung cancer data for ADC from $43B Seagen buy Despite an overall survival miss, Leerink Partners said Pfizer’s antibody-drug conjugate showed “promising” signals of efficacy in a subgroup of patients who had undergone only one prior line of treatment.
Definium’s LSD-based therapy elicits ‘profound’ efficacy in Phase 3 depression trial Results for Definium Therapeutics psychedelic candidate for major depressive disorder “exceeded expectations,” according to Stifel, while Jefferies called the efficacy data “profound.”
Intellia’s gene editor ‘keeps pace’ with Ionis in hereditary angioedema With a one-time dosing profile, Intellia Therapeutics’ gene editing asset could be “paradigm-shifting” for hereditary angioedema, according to Jefferies. The biotech anticipates market approval next year.
Neumora discards depression asset, lays off staffers after pair of late-stage flops Neumora Therapeutics is laying off 35% of workers after its most advanced asset failed a pair of Phase 3 studies, sending the biotech’s stock spiraling early Monday.
Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial Takeda eyes an FDA run for its investigational psoriasis pill after the drug elicited total skin clearance in more than 35% of patients at 16 weeks—more than 2.5 times that in controls taking Bristol Myers Squibb’s Sotyktu.
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer [Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney Function in IgA Nephropathy (IgAN) FDA Alignment to Advance ProstACT Global Phase 3 Trial INTENT Biologics Receives FDA Breakthrough Therapy Designation for PEP Biologic™ for its Phase 3 Ready Flagship Indication NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress 4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer |
Vistagen in freefall as social anxiety drug fails Phase 3
Despite the late-stage fail, Vistagen will nevertheless continue to push its drug candidate forward and meet with the FDA to align on a potential registrational path.
Golden Triangle still dominates, but talent and capital gaps slow biotech growth The U.K.’s core biotech cluster continues to produce world‑class science, but investors say limited talent mobility, uneven regional growth and tightening early‑ and mid‑stage capital are slowing the country’s ability to scale new companies.
Opinion: Innovation wins the contract. Complexity loses the renewal Innovation drives CROs to win new business, but unchecked customization creates complexity that undermines reproducibility, weakens renewals and leads to turnover—making standardization a strategic necessity, not a constraint.
Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes With the failure in chronic spontaneous urticaria, Evommune’s story is now centered on its anti-IL-18 therapy EVO301, Oppenheimer said, which in February elicited a 33% placebo-adjusted improvement in eczema severity.
Skyhawk CEO hopes FDA’s new uniQure position will translate to Huntington’s pill A recent FDA reversal sparked new hope for patients with Huntington’s disease. Flying under the radar, Skyhawk Therapeutics revealed 12-month functional data from a midstage trial of its own candidate showing improvements on a key disease measurement scale.
BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit BridgeBio Pharma plans to file for approval in the third quarter. If granted, the oral drug could present a “highly differentiated” option over current achondroplasia therapies, according to Jefferies.
4 ovarian cancer candidates to watch: GSK, Allarity and more Recent approvals for Corcept Therapeutics and Merck have injected momentum into the space, where GSK, Allarity Therapeutics, OSE Immunotherapies and others are advancing their own candidates.
Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears The positive ADHD data for Otsuka Pharmaceutical’s centanafadine is good news in what has of late been a mixed bag for the neuropsychiatric space.
BIO 2026: FDA’s IND initiative is a step toward normalization after slipshod year Policymaking at FDA has been anything but business as usual under the Trump administration, but former regulators cite the agency’s new investigational new drug pilot program as a sign of normalcy.
The Golden Triangle and the gaps: Rethinking UK biotech In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll hear from Hakan Goker, managing director at M Ventures and Maina Bhaman, partner at Sofinnova Partners. We explore the UK biotech ecosystem: from the Golden Triangle’s evolving role to the challenges of scaling companies, unlocking pension capital and staying globally competitive.
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B HLB Subsidiary Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Allergy Vaccine Candidate ITI-9001 Multitude Therapeutics Announces Encouraging Interim Phase I Results from Ongoing First-in-Human Study Evaluating its CDH17-directed Antibody-Drug-Conjugate, AMT-676, in patients with advanced CRC at the 2026 ESMO GI Cancer Congress Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 Medical University of Graz Enrolls First Patient in DEEPER CHALLENGE Trial Evaluating Spur® Peripheral Retrievable Scaffold System in a Select CLTI Cohort Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis Treos Bio Presents New Translational Data Showing PolyPEPI1018 Plus Anti-PD-L1 Immunotherapy Remodels the Tumor Immune Microenvironment in MSS Colorectal Cancer Alligator Announces First Patient Dosed in Investigator-Initiated Study of Intratumoral Mitazalimab in Early-Stage Breast Cancer Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis [Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney Function in IgA Nephropathy (IgAN) FDA Alignment to Advance ProstACT Global Phase 3 Trial Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia AOB Pharma and Biorasi to Partner to run Phase 2b in Moderate to Severe Acne 92Bio, Inc. Doses First Patient in Phase 1 Clinical Trial of NTB-928 in Platinum-Resistant Ovarian Cancer INTENT Biologics Receives FDA Breakthrough Therapy Designation for PEP Biologic™ for its Phase 3 Ready Flagship Indication 60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences |
|
|
| |||
|
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies
On June 30, 2026, the Food and Drug Administration approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi, Orca Bio) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGHVD)-free survival, in the treatment of adults with hematological malignancies.
Tue, 30 Jun 2026 00:00:02 -0700
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for two indications in adults with triple-negative breast cancer (TNBC).
Wed, 24 Jun 2026 00:00:02 -0700
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
Wed, 24 Jun 2026 00:00:02 -0700
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.
Fri, 12 Jun 2026 00:00:02 -0700
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Fri, 12 Jun 2026 00:00:02 -0700
FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).
Thu, 28 May 2026 00:00:02 -0700
FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Wed, 27 May 2026 00:00:02 -0700
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
Fri, 22 May 2026 00:00:02 -0700
FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer On May 15, 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab (with or without pertuzumab) and taxane-based treatment.
Fri, 15 May 2026 00:00:02 -0700
FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc. and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.
Fri, 15 May 2026 00:00:02 -0700
FDA approves oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
Wed, 13 May 2026 00:00:02 -0700
FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
Wed, 13 May 2026 00:00:02 -0700
FDA approves zenocutuzumab-zbco for advanced, unresectable or metastatic cholangiocarcinoma On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.
Fri, 08 May 2026 00:00:02 -0700
FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Fri, 01 May 2026 00:00:02 -0700
FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Wed, 25 Mar 2026 00:00:02 -0700
FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).
Fri, 20 Mar 2026 00:00:02 -0700
FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Thu, 05 Mar 2026 00:00:02 -0800
FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Thu, 26 Feb 2026 00:00:02 -0800
FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024.
Tue, 24 Feb 2026 00:00:02 -0800
FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Thu, 19 Feb 2026 00:00:02 -0800
FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
Tue, 10 Feb 2026 00:00:02 -0800
Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency Thu, 05 Feb 2026 00:00:02 -0800
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
Tue, 27 Jan 2026 00:00:02 -0800
FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.
Wed, 17 Dec 2025 00:00:02 -0800
|
Global, regional, and national burden of tuberculosis and multidrug-resistant tuberculosis by HIV status, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Lancet Infect Dis. 2026 Jul 1:S1473-3099(26)00295-1. doi: 10.1016/S1473-3099(26)00295-1. GBD 2023 TB HIV Collaborators Zonated mechanosensing by PIEZO1 controls liver regeneration. Science. 2026 Jul 2;393(6806):eaef0825. doi: 10.1126/science.aef0825. Epub 2026 Jul 2. Zhang Y, Sun Y, Xu G, Wu Y, Shi Z, Chang Z, Liu J, Pang K, Liu S, Wang H, Rong W, Shao Z, Liu X, He Y, Yan Y, Zhou B, Yuan Z, Zhang XF, Offermanns S, Wang S AARS1 promotes tumor progression and immune evasion via ATF6 lactylation-mediated tryptophan metabolism in hepatocellular carcinoma. Cell Metab. 2026 Jun 30:S1550-4131(26)00229-9. doi: 10.1016/j.cmet.2026.06.003. Wang Y, Li F, Li J, Huang T, Huang T, Zhang N, Li Y, Xun Z, Zhu Z, Tan Q, Zhao X, Zou L, Piao M, Li C, Sun B, Ma J, Chen P, Gu J, Dai S, Wang H, Ni M, Zhao H, Lu L A Case of Fingernail Onychomycosis due to Aspergillus flavus. Med Mycol J. 2016;57(2):E21-5. doi: 10.3314/mmj.57.E21. Noguchi H, Hiruma M, Miyashita A, Makino K, Miyata K, Ihn H [Expression of NF-κB, EGFR, and HER3 in castration-resistant prostate adenocarcinoma: a clinical and molecular study of 88 Moroccan patients]. Pan Afr Med J. 2026 Mar 26;53:144. doi: 10.11604/pamj.2026.53.144.51276. eCollection 2026. Sadaoui I, Sadaoui I, Joutei HAH, Benomar H, Nadifi S Lactate binds and inhibits the innate immune sensor STING to promote tumor immune evasion. Immunity. 2026 Jun 30:S1074-7613(26)00255-4. doi: 10.1016/j.immuni.2026.06.004. Guo D, Meng Y, Yang Q, Luo S, Jiang X, Zheng Y, Wu L, Li S, Jiang H, Li S, Wang Z, Li M, Wu Q, Xiao L, Zhu R, He X, Hu Y, Zhao H, Ye X, Tong Y, Fang J, Xu D, Xu J, Yuan Y, Lu Z Trends in NHANES Biomonitored Exposures in California and the United States following Enactment of California's Proposition 65. Environ Health Perspect. 2024 Oct;132(10):107007. doi: 10.1289/EHP13956. Epub 2024 Oct 21. Knox KE, Schwarzman MR, Rudel RA, Polsky C, Dodson RE Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis. N Engl J Med. 2026 Jul 2;395(1):44-53. doi: 10.1056/NEJMoa2600993. Torkildsen Ø, Brustad HK, Høgestøl EA, Alstadhaug KB, Bhan A, Flemmen HØ, Habbestad A, Høglund RAA, LeBlanc M, Lopen P, Lorentzen ÅR, Morsund ÅH, Lossius A, Lundby R, Nygaard GO, Rød BE, Simonsen CS, Steffensen L, Torgauten H, Piehl F, Wergeland S, Myhr KM; OVERLORD-MS Investigators Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma. N Engl J Med. 2026 Jul 2;395(1):32-43. doi: 10.1056/NEJMoa2518245. Choueiri TK, Motzer RJ, Karam JA, Yip W, Suárez C, Ye D, He Z, Caglevic C, Ferguson T, Chang YH, Rojas C, Iacovelli R, Ürün Y, Verzoni E, Vázquez Limón JC, Porta C, Uzzo RG, Lee JL, Venugopal B, McKay RR, Hammers H, Miyake H, Chahoud J, Liu H, Burgents JE, Sharma M, Powles TB; LITESPARK-022 Investigators Retraction Note: NSD2 targeting reverses plasticity and drug resistance in prostate cancer. Nature. 2026 Jun 30. doi: 10.1038/s41586-026-10816-w. Li JJ, Vasciaveo A, Karagiannis D, Sun Z, Gretarsson KH, Chen X, Ouerfelli O, Socciarelli F, Frankenstein Z, Dong H, Zou M, Yuan W, Yang G, Aizenman GM, Pannellini T, Xu X, Beltran H, Chen Y, Gardner K, Robinson BD, de Bono J, Gozani O, Abate-Shen C, Rubin MA, Loda M, Sawyers CL, Califano A, Lu C, Shen MM Steatosis shapes prognosis-defining liver metastasis heterogeneity in CRC. Nature. 2026 Jul 1. doi: 10.1038/s41586-026-10686-2. Peng-Winkler Y, Liu XZ, Verheul SML, Girondel C, Igelmann S, Rotter SM, Doukas M, Liu M, Vandekeere A, Planque M, Fernández-García J, Tabariès S, Buetas-Arcas M, Martínez-Martín S, Döbbe F, Demicco M, Vermeire I, Theile J, Ceuppens J, Haesevoets J, Tobarra-López E, Broekaert D, Bode JG, Luedde T, Vermeulen P, Tauriello DVF, Perez-Lopez R, Stegen S, Soucek L, De Oliveira T, Conradi LC, Siegel PM, Verhoef C, Fendt SM Inflammatory Pseudotumor of the Liver Presented in a Patient with Cholelithiasis. Cureus. 2018 Aug 29;10(8):e3231. doi: 10.7759/cureus.3231. Pantiora EV, Sakellaridis EP, Kontis EA, Fragulidis GP Dual tumour-myeloid targeting of glioblastoma with GPNMB CAR-T cells. Nature. 2026 Jul 1. doi: 10.1038/s41586-026-10641-1. Savage N, Grewal S, Shaikh MV, Zemp FJ, Mckenna D, Mikolajewicz N, Najem H, Pyczek J, Wei J, Taleb MAB, Asselstine LC, Anand A, Chafe SC, Zhai K, Maich WT, Chokshi CR, Patel H, Korman TE, Subapanditha M, Tabunshchyk Z, Tatari N, Miletic P, Chen D, Pacheco S, Omar AT, Wang B, Han H, Chan JA, Brown KR, Venugopal C, Kislinger T, Heimberger AB, Moffat J, Mahoney DJ, Singh SK Potential unmet need for gout diagnosis and treatment: capture-recapture analysis of a national administrative dataset. Rheumatology (Oxford). 2012 Oct;51(10):1820-4. doi: 10.1093/rheumatology/kes147. Epub 2012 Jun 20. Jackson G, Wright C, Thornley S, Taylor WJ, Te Karu L, Gow PJ, Arroll B, Gribben B, Dalbeth N, Winnard D SURVEY AND SUMMARY: exon-intron organization of genes in the slime mold Physarum polycephalum. Nucleic Acids Res. 2000 Sep 15;28(18):3411-6. doi: 10.1093/nar/28.18.3411. Trzcinska-Danielewicz J, Fronk J Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective. Lancet. 2026 Jun 30:S0140-6736(26)00512-X. doi: 10.1016/S0140-6736(26)00512-X. Blakney AK, Top KA, Cowling BJ, Larson HJ, Shattock RJ, Sadarangani M TROP2 targeting reveals therapy-driven cell state dynamics in colorectal cancer. Nature. 2026 Jul 1. doi: 10.1038/s41586-026-10705-2. Vaquero-Siguero N, Georgakopoulos N, Puschhof MC, Chiotakakos I, Meier J, Fey SK, Diamante G, Mastel M, Guiseris-Martinez A, Belthier G, Schleußner N, Volk J, Artmann C, Lim B, Koschny R, Wehling C, Ouyang KS, Günther M, Kuss S, Hoffmeister P, Mall M, Neumann J, Ormanns S, Schneider M, Schmidt T, Puschhof J, Trumpp A, van Rheenen J, Saez-Rodriguez J, Köhler BC, Jackstadt R Recurrent patterns of TOP1-mediated neuronal genomic damage shared by major neurodegenerative disorders. Cell. 2026 Jul 1:S0092-8674(26)00700-2. doi: 10.1016/j.cell.2026.06.013. Zhou Z, Luquette LJ, Dong G, Kim J, Ku J, Kim K, Ramesh N, Bae M, Caplin A, Shao DD, Sahile B, Essuman K, Goodman E, Miller MB, Huang AY, Nathan WJ, Nussenzweig A, Park PJ, Lagier-Tourenne C, Lee EA, Walsh CA Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609. N Engl J Med. 2026 Jun 29. doi: 10.1056/NEJMe2608684. Rubin EJ AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026). Circulation. 2026 Jun 29. doi: 10.1161/CIR.0000000000001455. Walsh MN, Kober L, Sliwa K, Adamo M, Agarwal A, Banerjee A, Bozkurt B, Cikes M, Damasceno A, Desai AS, Felker GM, Hogan G, Kinugawa K, Kittleson M, Lam CSP, McDonagh T, Metra M, Mullens W, Ribeiro ALP, Vaughn Y, Vest A; Joint American Heart Association (AHA)/American College of Cardiology (ACC)/European Society of Cardiology (ESC)/World Heart Federation (WHF) Task Force for the Universal Definition of Heart Failure in collaboration with the Heart Failure Society of America (HFSA), the Heart Failure Association (HFA) of the European Society of Cardiology, and the Japanese Heart Failure Society (JHFS) |
||